Skip to main content
WoMWeb of Medicine
SearchGraphHistory
Nephrology›Condition·Updated Jun 27, 2026·v1

Hyperkalemia

Hyperkalemia is a common and potentially lethal electrolyte disorder in CKD and patients on RAASi. Acute management prioritizes cardiac stabilization with IV calcium, then shifting potassium with insulin/dextrose, followed by removal with dialysis or binders. Long-term strategy centers on enabling continued cardiorenal-protective therapy by optimizing RAASi, adding SGLT2i, and using potassium binders to maintain normokalemia. The KDIGO risk heatmap guides monitoring intensity; the U-shaped mortality curve underscores the importance of avoiding both hypokalemia and hyperkalemia.

High Evidence271 references·1,513 words·7 min read·v1
hyperkalemianephrologyelectrolyte disorderCKDRAASipotassium bindersfinerenoneemergency management

Quick Reference

RxDrug of choiceIV calcium gluconate 10 mL of 10% solution for acute cardiac stabilization; regular insulin 10 units + 25 g dextrose for shifting.
AltAlternativesNebulized albuterol 10-20 mg (shifting); SZC 10 g TID (removal); patiromer 8.4 g BID (chronic); furosemide 40-80 mg IV (if preserved renal function).
⊘AvoidSPS (colonic necrosis); sodium bicarbonate as monotherapy (ineffective without acidosis); non-dihydropyridine CCBs in heart failure; NSAIDs in CKD.
DxTest of choiceSerum potassium level (heparinized plasma to exclude pseudohyperkalemia); TTKG = (urine K × plasma Osm)/(plasma K × urine Osm), <5 suggests impaired renal excretion.
ScKey scoreKDIGO GFR × albuminuria heatmap: very high risk (red) = eGFR <30 + UACR >300 mg/g, highest hyperkalemia and progression risk.
→When to referHyperkalemia requiring dialysis, refractory hyperkalemia despite binders, eGFR <20 with recurrent episodes, suspected genetic syndromes, transplant evaluation.
Calcium for ECG changes, insulin+dextrose for shifting, and dialysis for refractory cases; long-term, preserve RAASi/MRA with SGLT2i and potassium binders, never stop RAASi for mild hyperkalemia.
Hyperkalemia (serum K+ >5.0 mEq/L) is a potentially life-threatening electrolyte disorder from impaired renal excretion, transcellular shifts, or excessive intake. It requires urgent differentiation from pseudohyperkalemia and ECG-guided management to prevent cardiac arrest [10].

Overview and Recommendations

Background

  • •Hyperkalemia, serum potassium >5.0 mEq/L, affects up to 10% of hospitalized patients and carries a 1-year mortality of up to 48% in advanced CKD when sustained >5.5 mmol/L, driven largely by arrhythmic sudden death. The prevalence rises steeply from 2% at eGFR 60-90 mL/min to 42% at eGFR <20 mL/min.
  • •The kidney normally excretes 90% of daily potassium intake (~1 mmol/kg/day) through aldosterone-driven secretion via the ROMK channel in the aldosterone-sensitive distal nephron. Hyperkalemia arises when this excretory capacity is exceeded due to reduced functional nephron mass (CKD), impaired aldosterone signaling (hypoaldosteronism, RAASi), or antagonism of the WNK-SPAK-NCC axis that controls distal sodium delivery.
  • •Classification by pathophysiology, impaired excretion (CKD, hypoaldosteronism, medications), transcellular shift (acidosis, insulin deficiency, beta-blockade, digoxin toxicity), excessive intake (supplements, salt substitutes, tumor lysis), or pseudohyperkalemia (hemolysis, thrombocytosis), guides both acute and chronic management.
  • •The most common cause in clinical practice is the combination of CKD (especially stage 3b or worse) and medications that impair renal potassium excretion, RAAS inhibitors, NSAIDs, potassium-sparing diuretics, calcineurin inhibitors, and trimethoprim-sulfamethoxazole. An identifiable precipitant is present in >80% of hyperkalemia episodes.

Evaluation

  • •Suspect hyperkalemia in any patient with CKD, heart failure, diabetes, or those on RAASi, MRAs, NSAIDs, or potassium supplements who present with ECG changes, muscle weakness, or unexplained arrhythmias.
  • •Confirm true hyperkalemia by repeating the measurement with a heparinized plasma sample to exclude pseudohyperkalemia from hemolysis, thrombocytosis (platelets >500,000/μL), or leukocytosis (WBC >100,000/μL).
  • •Obtain a stat ECG: look for peaked T waves (K+ 5.5-6.5), prolonged PR interval, loss of P wave, widened QRS >0.12 sec, or sine-wave pattern. Up to 50% of patients with K+ >6.5 may have a normal ECG, correlate with clinical context.
  • •Assess urgency: K+ >6.0 with ECG changes or any K+ >6.5 is severe and requires immediate IV calcium. Mild (5.0-5.5) and moderate (5.6-6.0) without ECG changes allow focused workup first.
  • •Perform a focused history: medication list (recent RAASi, MRA, NSAID, heparin, TMP-SMX, calcineurin inhibitor), dietary potassium intake (salt substitutes, high-K foods), symptoms of muscle weakness or palpitations, history of CKD, diabetes, heart failure, or adrenal disease (including immune checkpoint inhibitor use).
  • •Examine for signs of volume depletion (suggests mineralocorticoid deficiency) or volume overload (suggests CKD/heart failure), ascending muscle weakness with areflexia, and signs of tumor lysis or rhabdomyolysis.
  • •Order initial labs: serum creatinine/eGFR, bicarbonate (non-anion gap acidosis => type 4 RTA), glucose, and spot urine potassium with osmolality to calculate the transtubular potassium gradient (TTKG). TTKG <5 indicates impaired renal excretion; TTKG >7 suggests extrarenal cause or excessive intake.
  • •If TTKG <5 and no obvious medication cause, measure aldosterone and renin: low aldosterone with low renin suggests hyporeninemic hypoaldosteronism (type 4 RTA, common in diabetic nephropathy); low aldosterone with high renin suggests primary adrenal insufficiency (check cortisol and ACTH).
  • •Consider imaging only if adrenal insufficiency is suspected (CT adrenals for hemorrhage, metastases, or atrophy). Renal biopsy is not indicated for hyperkalemia alone.
  • •In the ICU or emergency setting, use AI-enhanced ECG algorithms (AUC 0.88-0.92) to rapidly identify patients with K+ >6.0 who may be asymptomatic.

Management

  • •For severe hyperkalemia (K+ >6.0 with ECG changes or any K+ >6.5): immediately administer 10 mL of 10% calcium gluconate IV over 2-5 minutes (or 5 mL calcium chloride via central line). Repeat once if ECG changes persist after 5 minutes. Do not give calcium via same line as bicarbonate.
  • •Simultaneously, give regular insulin 10 units IV bolus + 25 g dextrose IV (50 mL D50W). Onset in 15-30 min; K+ drops 0.5-1.0 mmol/L over 4-6 hours. Monitor blood glucose hourly for 6 hours (hypoglycemia in 10-20%, treat with additional D50 if needed).
  • •In patients with baseline blood glucose <126 mg/dL, give dextrose first; if glucose >250 mg/dL, dextrose may be reduced or omitted. Consider 50 g dextrose (D25W 200 mL) in CKD patients at high risk of hypoglycemia.
  • •Add nebulized albuterol 10-20 mg for additive effect if K+ does not drop by ≥0.5 mmol/L within 1 hour. Do not use sodium bicarbonate as monotherapy, reserve for concurrent metabolic acidosis with pH <7.2.
  • •For definitive potassium removal after stabilization: use loop diuretics (furosemide 40-80 mg IV) if preserved renal function, or initiate novel potassium binders, sodium zirconium cyclosilicate (SZC) 10 g PO TID for up to 48 hours (lowers K+ by 0.7-1.1 mmol/L in 24 h) or patiromer 8.4 g PO BID (onset 4-7 days).
  • •Initiate emergent hemodialysis (IHD) if any AEIOU criterion is met: Acidosis (pH <7.15), Electrolyte (K+ >6.5 despite shifting, or >6.0 with ECG changes), Intoxication (lithium, salicylates), Overload (pulmonary edema with oliguria), Uremia (symptomatic). Dialysate K+ 2.0-3.0 mEq/L; single session typically lowers K+ from 6.5 to 4.0.
  • •Do not use sodium polystyrene sulfonate (SPS) for acute management, poor efficacy and risk of colonic necrosis. Avoid giving calcium and bicarbonate through the same IV line. Do not delay dialysis awaiting medical therapy when AEIOU criteria are present.
  • •For chronic management, never stop RAASi or MRA for isolated mild hyperkalemia (K+ 5.0-5.5). Optimize all four pillars of GDMT: RAASi (target max tolerated dose), beta-blocker, MRA (finerenone preferred in CKD/albuminuria), and SGLT2i (dapagliflozin 10 mg or empagliflozin 10 mg daily if eGFR ≥20).
  • •Start finerenone at eGFR ≥60: 20 mg once daily; eGFR 25-60: 10 mg once daily. Monitor K+ and eGFR at 4 weeks, then every 3-6 months. If K+ rises to 5.5-6.0, reduce dose; if >6.0, hold and correct, then resume half-dose with potassium binder.
  • •Add SGLT2i to finerenone to attenuate hyperkalemia risk (CONFIDENCE: combination reduced hyperkalemia >6.0 by 44% vs finerenone alone). SGLT2i reduce RAASi discontinuation by 15% (HR 0.85).
  • •When hyperkalemia limits RAASi/MRA titration, add a potassium binder (SZC 5 g daily or patiromer 8.4 g daily) rather than discontinuing protective therapy. Do not use SPS as first-line chronic binder.
  • •Restrict dietary potassium to <3 g/day (75 mmol/day) in advanced CKD, but balance against cardiovascular benefits of plant-based foods. Avoid potassium-containing salt substitutes (25% KCl raises K+ by 0.3-0.5). Discontinue NSAIDs and potassium-sparing diuretics.
  • •Refer to nephrology for: hyperkalemia requiring dialysis, refractory hyperkalemia despite optimized medical therapy and binders, eGFR <20 mL/min with recurrent hyperkalemia, suspected genetic syndromes (pseudohypoaldosteronism, Gordon syndrome), or consideration for kidney transplantation.
  • •In hemodialysis patients, aim for predialysis K+ 4.0-5.5 mmol/L. Use dialysate K+ 2.0-3.0 mEq/L; consider adding SZC 5 g on non-dialysis days to maintain target. Fludrocortisone 0.1 mg daily may help in hypoaldosteronism.
  • •In pregnancy: acute management is same as non-pregnant adults. SPS is contraindicated; patiromer and SZC have no safety data. For K+ >6.0 at term, consider expedited delivery.
  • •In children: use age-adjusted calcium (0.5-1 mL/kg of 10% calcium gluconate) and insulin (0.1-0.2 U/kg with 0.5-1 g/kg dextrose). Neonates: dextrose 2 mL/kg D10 without insulin.
  • •In older adults: optimal K+ range is narrower (4.0-5.0). NSAID avoidance and careful RAASi titration with K+ checks every 2-4 weeks are critical.

Board Review — High Yield

  • •Pseudohyperkalemia, In vitro artifact from hemolysis, thrombocytosis, or leukocytosis; repeat with heparinized plasma.
  • •TTKG <5, Indicates impaired renal potassium excretion (hypoaldosteronism, CKD, medications); TTKG >7 suggests extrarenal cause.
  • •Type 4 RTA, Hyperkalemic, non-anion gap metabolic acidosis from aldosterone deficiency or resistance; seen in diabetic nephropathy.
  • •WNK-SPAK-NCC axis, Mutations in WNK1/4 cause familial hyperkalemic hypertension (Gordon syndrome); constitutively active SPAK drives hyperkalemia.
  • •Finerenone, Nonsteroidal MRA; lowers kidney composite outcome by 23% (HR 0.77) with lower hyperkalemia risk than spironolactone.
  • •CONFIDENCE trial, Finerenone + empagliflozin reduces albuminuria by 62% and lowers hyperkalemia >6.0 by 44% vs finerenone alone.
  • •DIALIZE-Outcomes, SZC maintained predialysis K+ 4.4 vs 5.0 mmol/L and trended toward reduced sudden cardiac death (HR 0.71) but trial stopped early.
  • •U-shaped mortality curve, In CKD, optimal K+ is 4.0-5.0 mmol/L; K+ >5.5 increases death risk by 27% (HR 1.27) vs reference.
  • •RAASi continuation, Stopping RAASi after hyperkalemia increases mortality by 40% (HR 1.40), resume with loop diuretic or potassium binder.
  • •AEIOU criteria, Acidosis, Electrolyte, Intoxication, Overload, Uremia, triggers for emergent dialysis.

Deep Dive — Evidence Details

References

  1. [1]

    Belot A, Ranchin B, Fichtner C et al.. “Pseudohypoaldosteronisms, report on a 10-patient series.” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2008). PMID: 18424465 ↗

    L4CASE_REPORTCited in: Definition, Classification and Nomenclature, Clinical Presentation, Diagnosis and Workup
  2. [2]

    Li X, Liu C, Mao Z et al.. “Timing of renal replacement therapy initiation for acute kidney injury in critically ill patients: a systematic review of randomized clinical trials with meta-analysis and trial sequential analysis.” Critical care (London, England) (2021). PMID: 33407756 ↗

    L1SR_OBSCited in: Definition, Classification and Nomenclature
  3. [3]

    Pun PH, Herzog CA, Middleton JP. “Improving ascertainment of sudden cardiac death in patients with end stage renal disease.” Clinical journal of the American Society of Nephrology : CJASN (2011). PMID: 22076878 ↗

    L3OTHERCited in: Definition, Classification and Nomenclature
  4. [4]

    Kim IS, Kim S, Yoo TH et al.. “Diagnosis and treatment of hypertension in dialysis patients: a systematic review.” Clinical hypertension (2023). PMID: 37653470 ↗

    L5SR_OBSCited in: Definition, Classification and Nomenclature
  5. [5]

    Alnajjar AZ, Ibrahim AI, Ellebedy M. “Hyperkalemia-induced Brugada phenocopy: a systematic review of case reports.” Clinical research in cardiology : official journal of the German Cardiac Society (2025). PMID: 39964614 ↗

    L4SR_OBSCited in: Definition, Classification and Nomenclature
  6. [6]

    Petrone P, Espinoza-Villalobos S, Baltazar GA et al.. “Fatal and non-fatal injuries due to suspension trauma syndrome: A systematic review of definition, pathophysiology, and management controversies.” World journal of emergency medicine (2021). PMID: 34512820 ↗

    L5SR_OBSCited in: Definition, Classification and Nomenclature
  7. [7]

    Nozu K, Fu XJ, Kaito H et al.. “A novel mutation in KCNJ1 in a Bartter syndrome case diagnosed as pseudohypoaldosteronism.” Pediatric nephrology (Berlin, Germany) (2007). PMID: 17401586 ↗

    L4CASE_REPORTCited in: Definition, Classification and Nomenclature
  8. [8]

    Guo ZA, Yu CJ, Liu G et al.. “[Treatment of stage 3b diabetic kidney disease patients with macroalbuminuria by qizhi jiangtang capsule: a multicenter randomized control clinical study].” Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine (2014). PMID: 25335326 ↗

    L1RCTCited in: Definition, Classification and Nomenclature
  9. [9]

    Yaseen H. “Nonoliguric hyperkalemia in neonates: a case-controlled study.” American journal of perinatology (2008). PMID: 19031348 ↗

    L3CASE_CONTROLCited in: Definition, Classification and Nomenclature
  10. [10]

    Gupta AA, Self M, Mueller M et al.. “Dispelling myths and misconceptions about the treatment of acute hyperkalemia.” The American journal of emergency medicine (2021). PMID: 34890894 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification and Nomenclature
  11. [11]

    Hiremath S, Fergusson DA, Fergusson N et al.. “Renin-Angiotensin System Blockade and Long-term Clinical Outcomes in Kidney Transplant Recipients: A Meta-analysis of Randomized Controlled Trials.” American journal of kidney diseases : the official journal of the National Kidney Foundation (2016). PMID: 27712852 ↗

    L1SR_MA_RCTCited in: Pathophysiology and Mechanism, Long-term and Definitive Management
  12. [12]

    Webb NJ, Shahinfar S, Wells TG et al.. “Losartan and enalapril are comparable in reducing proteinuria in children.” Kidney international (2012). PMID: 22739977 ↗

    L2RCTCited in: Pathophysiology and Mechanism, Epidemiology, Etiology and Risk Factors, Clinical Presentation, Diagnosis and Workup, Prognosis and Natural History, Special Populations and Prevention
  13. [13]

    Weir MR, Bakris GL, Gross C et al.. “Treatment with patiromer decreases aldosterone in patients with chronic kidney disease and hyperkalemia on renin-angiotensin system inhibitors.” Kidney international (2016). PMID: 27350174 ↗

    L1RCTCited in: Pathophysiology and Mechanism, Clinical Presentation, Diagnosis and Workup, Staging and Risk Stratification (KDIGO), Renal Replacement Therapy, Transplantation and Electrolyte/Acid-Base Management, Complications, Special Populations and Prevention
  14. [14]

    Farese S, Kruse A, Pasch A et al.. “Glycyrrhetinic acid food supplementation lowers serum potassium concentration in chronic hemodialysis patients.” Kidney international (2009). PMID: 19641483 ↗

    L1RCTCited in: Pathophysiology and Mechanism, Special Populations and Prevention
  15. [15]

    Bomback AS, Kshirsagar AV, Amamoo MA et al.. “Change in proteinuria after adding aldosterone blockers to ACE inhibitors or angiotensin receptor blockers in CKD: a systematic review.” American journal of kidney diseases : the official journal of the National Kidney Foundation (2008). PMID: 18215698 ↗

    L1SR_OBSCited in: Pathophysiology and Mechanism, Clinical Presentation, Diagnosis and Workup, Long-term and Definitive Management, Complications, Prognosis and Natural History
  16. [16]

    Ku E, Copeland TP, McCulloch CE et al.. “Intensive Home Blood Pressure Lowering in Patients With Advanced CKD.” American journal of kidney diseases : the official journal of the National Kidney Foundation (2024). PMID: 39427725 ↗

    L2RCTCited in: Pathophysiology and Mechanism, Clinical Presentation, Diagnosis and Workup, Long-term and Definitive Management, Complications, Special Populations and Prevention
  17. [17]

    Fernandez Juarez G, Luño J, Barrio V et al.. “Effect of dual blockade of the renin-angiotensin system on the progression of type 2 diabetic nephropathy: a randomized trial.” American journal of kidney diseases : the official journal of the National Kidney Foundation (2012). PMID: 22939518 ↗

    L1RCTCited in: Pathophysiology and Mechanism, Special Populations and Prevention
  18. [18]

    Heerspink HJL, Birkenfeld AL, Cherney DZI et al.. “Finerenone in Type 1 Diabetes and Chronic Kidney Disease.” The New England journal of medicine (2026). PMID: 41780000 ↗

    L1RCTCited in: Pathophysiology and Mechanism, Epidemiology, Etiology and Risk Factors, Clinical Presentation, Diagnosis and Workup, Staging and Risk Stratification (KDIGO), Long-term and Definitive Management, Renal Replacement Therapy, Transplantation and Electrolyte/Acid-Base Management, Complications, Prognosis and Natural History, Special Populations and Prevention
  19. [19]

    Provenzano M, Puchades MJ, Garofalo C et al.. “Albuminuria-Lowering Effect of Dapagliflozin, Eplerenone, and Their Combination in Patients with Chronic Kidney Disease: A Randomized Crossover Clinical Trial.” Journal of the American Society of Nephrology : JASN (2022). PMID: 35440501 ↗

    L1RCTCited in: Pathophysiology and Mechanism, Clinical Presentation, Diagnosis and Workup, Staging and Risk Stratification (KDIGO), Long-term and Definitive Management, Complications, Prognosis and Natural History
  20. [20]

    Solomon SD, McMurray JJV, Vaduganathan M et al.. “Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction.” The New England journal of medicine (2024). PMID: 39225278 ↗

    L1RCTCited in: Pathophysiology and Mechanism, Epidemiology, Etiology and Risk Factors, Long-term and Definitive Management, Complications, Special Populations and Prevention
  21. [21]

    Bakris GL, Agarwal R, Anker SD et al.. “Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes.” The New England journal of medicine (2020). PMID: 33264825 ↗

    L1RCTCited in: Pathophysiology and Mechanism, Epidemiology, Etiology and Risk Factors, Clinical Presentation, Diagnosis and Workup, Staging and Risk Stratification (KDIGO), Long-term and Definitive Management, Renal Replacement Therapy, Transplantation and Electrolyte/Acid-Base Management, Complications, Prognosis and Natural History, Special Populations and Prevention
  22. [22]

    Agarwal R, Green JB, Heerspink HJL et al.. “Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes.” The New England journal of medicine (2025). PMID: 40470996 ↗

    L1RCTCited in: Pathophysiology and Mechanism, Clinical Presentation, Diagnosis and Workup, Staging and Risk Stratification (KDIGO), Long-term and Definitive Management, Complications, Prognosis and Natural History, Special Populations and Prevention
  23. [23]

    Bi Y, Li M, Liu Y et al.. “Intensive Blood-Pressure Control in Patients with Type 2 Diabetes.” The New England journal of medicine (2024). PMID: 39555827 ↗

    L1RCTCited in: Pathophysiology and Mechanism, Epidemiology, Etiology and Risk Factors, Clinical Presentation, Diagnosis and Workup, Long-term and Definitive Management, Renal Replacement Therapy, Transplantation and Electrolyte/Acid-Base Management, Complications, Special Populations and Prevention
  24. [24]

    Solomon SD, McMurray JJV, Anand IS et al.. “Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction.” The New England journal of medicine (2019). PMID: 31475794 ↗

    L1RCTCited in: Pathophysiology and Mechanism, Epidemiology, Etiology and Risk Factors, Long-term and Definitive Management, Complications, Special Populations and Prevention
  25. [25]

    Pitt B, Pfeffer MA, Assmann SF et al.. “Spironolactone for heart failure with preserved ejection fraction.” The New England journal of medicine (2014). PMID: 24716680 ↗

    L1RCTCited in: Pathophysiology and Mechanism, Epidemiology, Etiology and Risk Factors, Long-term and Definitive Management, Complications, Special Populations and Prevention
  26. [26]

    Packham DK, Rasmussen HS, Lavin PT et al.. “Sodium zirconium cyclosilicate in hyperkalemia.” The New England journal of medicine (2014). PMID: 25415807 ↗

    L1RCTCited in: Pathophysiology and Mechanism, Acute Management, Long-term and Definitive Management, Renal Replacement Therapy, Transplantation and Electrolyte/Acid-Base Management, Complications, Special Populations and Prevention
  27. [27]

    Weir MR, Bakris GL, Bushinsky DA et al.. “Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors.” The New England journal of medicine (2014). PMID: 25415805 ↗

    L4RCTCited in: Pathophysiology and Mechanism, Acute Management, Renal Replacement Therapy, Transplantation and Electrolyte/Acid-Base Management
  28. [28]

    Gaudry S, Hajage D, Schortgen F et al.. “Initiation Strategies for Renal-Replacement Therapy in the Intensive Care Unit.” The New England journal of medicine (2016). PMID: 27181456 ↗

    L1RCTCited in: Pathophysiology and Mechanism, Epidemiology, Etiology and Risk Factors, Clinical Presentation, Staging and Risk Stratification (KDIGO), Acute Management, Renal Replacement Therapy, Transplantation and Electrolyte/Acid-Base Management, Prognosis and Natural History
  29. [29]

    Torres VE, Abebe KZ, Chapman AB et al.. “Angiotensin blockade in late autosomal dominant polycystic kidney disease.” The New England journal of medicine (2014). PMID: 25399731 ↗

    L1RCTCited in: Pathophysiology and Mechanism, Epidemiology, Etiology and Risk Factors, Clinical Presentation, Diagnosis and Workup, Staging and Risk Stratification (KDIGO), Prognosis and Natural History
  30. [30]

    Fried LF, Emanuele N, Zhang JH et al.. “Combined angiotensin inhibition for the treatment of diabetic nephropathy.” The New England journal of medicine (2013). PMID: 24206457 ↗

    L1RCTCited in: Pathophysiology and Mechanism, Diagnosis and Workup, Prognosis and Natural History
  31. [31]

    Whitlock R, Leon SJ, Manacsa H et al.. “The association between dual RAAS inhibition and risk of acute kidney injury and hyperkalemia in patients with diabetic kidney disease: a systematic review and meta-analysis.” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2023). PMID: 37309038 ↗

    L1SR_OBSCited in: Pathophysiology and Mechanism, Acute Management, Long-term and Definitive Management, Renal Replacement Therapy, Transplantation and Electrolyte/Acid-Base Management
  32. [32]

    Munoz Mendoza J, Weir MR, Anker SD et al.. “Finerenone in People with CKD, Type 2 Diabetes, and History of Nephrectomy.” Clinical journal of the American Society of Nephrology : CJASN (2026). PMID: 41533467 ↗

    L2RCTCited in: Pathophysiology and Mechanism, Clinical Presentation, Diagnosis and Workup, Staging and Risk Stratification (KDIGO), Long-term and Definitive Management, Renal Replacement Therapy, Transplantation and Electrolyte/Acid-Base Management, Complications, Prognosis and Natural History, Special Populations and Prevention
  33. [33]

    Sarafidis P, Agarwal R, Pitt B et al.. “Outcomes with Finerenone in Participants with Stage 4 CKD and Type 2 Diabetes: A FIDELITY Subgroup Analysis.” Clinical journal of the American Society of Nephrology : CJASN (2023). PMID: 36927680 ↗

    L2RCTCited in: Pathophysiology and Mechanism, Epidemiology, Etiology and Risk Factors, Diagnosis and Workup, Staging and Risk Stratification (KDIGO), Long-term and Definitive Management, Complications, Prognosis and Natural History, Special Populations and Prevention
  34. [34]

    Van Buren PN, Adams-Huet B, Nguyen M et al.. “Potassium handling with dual renin-angiotensin system inhibition in diabetic nephropathy.” Clinical journal of the American Society of Nephrology : CJASN (2014). PMID: 24408116 ↗

    L2RCTCited in: Pathophysiology and Mechanism, Clinical Presentation, Diagnosis and Workup
  35. [35]

    Vaduganathan M, Green JB, Heerspink HJL et al.. “Simultaneous initiation of finerenone and empagliflozin across the spectrum of kidney risk in the CONFIDENCE trial.” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2025). PMID: 40886054 ↗

    L1RCTCited in: Pathophysiology and Mechanism, Epidemiology, Etiology and Risk Factors, Clinical Presentation, Diagnosis and Workup, Staging and Risk Stratification (KDIGO), Long-term and Definitive Management, Complications, Prognosis and Natural History, Special Populations and Prevention
  36. [36]

    Leon SJ, Whitlock R, Rigatto C et al.. “Hyperkalemia-Related Discontinuation of Renin-Angiotensin-Aldosterone System Inhibitors and Clinical Outcomes in CKD: A Population-Based Cohort Study.” American journal of kidney diseases : the official journal of the National Kidney Foundation (2022). PMID: 35085685 ↗

    L2COHORTCited in: Pathophysiology and Mechanism, Epidemiology, Etiology and Risk Factors, Long-term and Definitive Management, Renal Replacement Therapy, Transplantation and Electrolyte/Acid-Base Management, Complications
  37. [37]

    Wiebe N, Klarenbach SW, Allan GM et al.. “Potentially preventable hospitalization as a complication of CKD: a cohort study.” American journal of kidney diseases : the official journal of the National Kidney Foundation (2014). PMID: 24731738 ↗

    L2COHORTCited in: Pathophysiology and Mechanism, Epidemiology, Etiology and Risk Factors, Diagnosis and Workup, Prognosis and Natural History, Special Populations and Prevention
  38. [38]

    Fletcher RA, Jongs N, Chertow GM et al.. “Effect of SGLT2 Inhibitors on Discontinuation of Renin-angiotensin System Blockade: A Joint Analysis of the CREDENCE and DAPA-CKD Trials.” Journal of the American Society of Nephrology : JASN (2023). PMID: 37876229 ↗

    L2SR_OBSCited in: Pathophysiology and Mechanism, Long-term and Definitive Management, Complications
  39. [39]

    Bianchi S, Regolisti G. “Pivotal clinical trials, meta-analyses and current guidelines in the treatment of hyperkalemia.” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2019). PMID: 31800075 ↗

    L5TRIAL_NONRANDOMCited in: Pathophysiology and Mechanism, Epidemiology, Etiology and Risk Factors, Acute Management, Long-term and Definitive Management, Renal Replacement Therapy, Transplantation and Electrolyte/Acid-Base Management
  40. [40]

    Palmer BF, Clegg DJ. “Physiology and Pathophysiology of Potassium Homeostasis: Core Curriculum 2019.” American journal of kidney diseases : the official journal of the National Kidney Foundation (2019). PMID: 31227226 ↗

    L5CASE_REPORTCited in: Pathophysiology and Mechanism, Renal Replacement Therapy, Transplantation and Electrolyte/Acid-Base Management, Complications, Prognosis and Natural History
  41. [41]

    Felsenfeld AJ, Levine BS. “Approach to treatment of hypophosphatemia.” American journal of kidney diseases : the official journal of the National Kidney Foundation (2012). PMID: 22863286 ↗

    L5CASE_REPORTCited in: Pathophysiology and Mechanism, Epidemiology, Etiology and Risk Factors
  42. [42]

    Mangray M, Vella JP. “Hypertension after kidney transplant.” American journal of kidney diseases : the official journal of the National Kidney Foundation (2011). PMID: 21251543 ↗

    L5CASE_REPORTCited in: Pathophysiology and Mechanism, Clinical Presentation, Diagnosis and Workup, Long-term and Definitive Management, Complications, Prognosis and Natural History
  43. [43]

    Asmar A, Mohandas R, Wingo CS. “A physiologic-based approach to the treatment of a patient with hypokalemia.” American journal of kidney diseases : the official journal of the National Kidney Foundation (2012). PMID: 22901631 ↗

    L4CASE_REPORTCited in: Pathophysiology and Mechanism, Clinical Presentation, Diagnosis and Workup, Staging and Risk Stratification (KDIGO)
  44. [44]

    Clase CM, Carrero JJ, Ellison DH et al.. “Potassium homeostasis and management of dyskalemia in kidney diseases: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.” Kidney international (2019). PMID: 31706619 ↗

    L5OTHERCited in: Pathophysiology and Mechanism, Diagnosis and Workup, Staging and Risk Stratification (KDIGO), Acute Management, Renal Replacement Therapy, Transplantation and Electrolyte/Acid-Base Management, Complications, Prognosis and Natural History
  45. [45]

    Georgianos PI, Agarwal R. “Revisiting RAAS blockade in CKD with newer potassium-binding drugs.” Kidney international (2017). PMID: 29276100 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism, Epidemiology, Etiology and Risk Factors, Clinical Presentation, Diagnosis and Workup, Acute Management, Long-term and Definitive Management, Renal Replacement Therapy, Transplantation and Electrolyte/Acid-Base Management
  46. [46]

    Shavit L, Lifschitz MD, Epstein M. “Aldosterone blockade and the mineralocorticoid receptor in the management of chronic kidney disease: current concepts and emerging treatment paradigms.” Kidney international (2012). PMID: 22336987 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism, Epidemiology, Etiology and Risk Factors, Staging and Risk Stratification (KDIGO), Acute Management, Long-term and Definitive Management, Renal Replacement Therapy, Transplantation and Electrolyte/Acid-Base Management, Complications, Prognosis and Natural History
  47. [47]

    Subramanya AR, Yang CL, McCormick JA et al.. “WNK kinases regulate sodium chloride and potassium transport by the aldosterone-sensitive distal nephron.” Kidney international (2006). PMID: 16820787 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism, Complications
  48. [48]

    Murillo-de-Ozores AR, Carbajal-Contreras H, Magaña-Ávila GR et al.. “Multiple molecular mechanisms are involved in the activation of the kidney sodium-chloride cotransporter by hypokalemia.” Kidney international (2022). PMID: 35870644 ↗

    L5OTHERCited in: Pathophysiology and Mechanism, Renal Replacement Therapy, Transplantation and Electrolyte/Acid-Base Management
  49. [49]

    Bakris GL. “Dual RAAS blockade is desirable in kidney disease: con.” Kidney international (2010). PMID: 20664560 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism, Clinical Presentation, Diagnosis and Workup, Long-term and Definitive Management
  50. [50]

    Banki E, Fisi V, Moser S et al.. “Specific disruption of calcineurin-signaling in the distal convoluted tubule impacts the transcriptome and proteome, and causes hypomagnesemia and metabolic acidosis.” Kidney international (2021). PMID: 34252449 ↗

    L5OTHERCited in: Pathophysiology and Mechanism
  51. [51]

    Smyth A, Dunkler D, Gao P et al.. “The relationship between estimated sodium and potassium excretion and subsequent renal outcomes.” Kidney international (2014). PMID: 24918156 ↗

    L4OTHERCited in: Pathophysiology and Mechanism, Diagnosis and Workup, Staging and Risk Stratification (KDIGO), Long-term and Definitive Management, Renal Replacement Therapy, Transplantation and Electrolyte/Acid-Base Management, Prognosis and Natural History
  52. [52]

    Fotheringham J, Weatherley N, Kawar B et al.. “The body composition and excretory burden of lean, obese, and severely obese individuals has implications for the assessment of chronic kidney disease.” Kidney international (2014). PMID: 24717300 ↗

    L4OTHERCited in: Pathophysiology and Mechanism, Diagnosis and Workup, Staging and Risk Stratification (KDIGO), Complications, Prognosis and Natural History
  53. [53]

    Falodia R, Alokozay E, Idrees M et al.. “Efficacy and Safety of Baxdrostat for Hypertension: A Systematic Review and Meta-Analysis of Three Phase 2/3 Randomized Controlled Trials.” Clinical cardiology (2026). PMID: 42334050 ↗

    L1SR_MA_RCTCited in: Pathophysiology and Mechanism, Long-term and Definitive Management, Complications
  54. [54]

    Alam U, Rath S, Javed J et al.. “Efficacy and safety of lorundrostat in uncontrolled hypertension: A GRADE-assessed systematic review and meta-analysis of randomized controlled trials.” Naunyn-Schmiedeberg's archives of pharmacology (2025). PMID: 41379320 ↗

    L1SR_MA_RCTCited in: Pathophysiology and Mechanism, Long-term and Definitive Management, Complications
  55. [55]

    Mubeen M, Rai KD, Sangtiani AK et al.. “Efficacy and Safety of Lorundrostat in Uncontrolled and/or Treatment Resistant Hypertension: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.” High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension (2025). PMID: 41107674 ↗

    L1SR_MA_RCTCited in: Pathophysiology and Mechanism, Diagnosis and Workup, Special Populations and Prevention
  56. [56]

    Wu J, Pei Y, Wu J et al.. “Efficacy and safety of mineralocorticoid receptor antagonists in heart failure: a meta-analysis of randomized controlled trials.” BMC cardiovascular disorders (2025). PMID: 41023853 ↗

    L1SR_MA_RCTCited in: Pathophysiology and Mechanism, Staging and Risk Stratification (KDIGO)
  57. [57]

    Epstein M, Lifschitz MD. “Potassium homeostasis and dyskalemias: the respective roles of renal, extrarenal, and gut sensors in potassium handling.” Kidney international supplements (2016). PMID: 30675414 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism
  58. [58]

    Drennan IR, Berg KM, Böttiger BW et al.. “Advanced Life Support: 2025 International Liaison Committee on Resuscitation Consensus on Science With Treatment Recommendations.” Circulation (2025). PMID: 41122842 ↗

    L1GUIDELINECited in: Pathophysiology and Mechanism, Diagnosis and Workup, Acute Management
  59. [59]

    Joshi S, McMacken M, Kalantar-Zadeh K. “Plant-Based Diets for Kidney Disease: A Guide for Clinicians.” American journal of kidney diseases : the official journal of the National Kidney Foundation (2020). PMID: 33075387 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism, Epidemiology, Etiology and Risk Factors, Long-term and Definitive Management, Renal Replacement Therapy, Transplantation and Electrolyte/Acid-Base Management, Complications, Prognosis and Natural History
  60. [60]

    Mclean A, Nath M, Sawhney S. “Population Epidemiology of Hyperkalemia: Cardiac and Kidney Long-term Health Outcomes.” American journal of kidney diseases : the official journal of the National Kidney Foundation (2021). PMID: 34419518 ↗

    L2OTHERCited in: Pathophysiology and Mechanism, Epidemiology, Etiology and Risk Factors, Diagnosis and Workup, Renal Replacement Therapy, Transplantation and Electrolyte/Acid-Base Management, Prognosis and Natural History
  61. [61]

    Jiang N, Zhang Y, Tang Y et al.. “Comparative efficacy and safety of different SGLT2 inhibitor-based combination strategies in HFrEF: a systematic review and network meta-analysis.” Frontiers in endocrinology (2026). PMID: 41550872 ↗

    L1SR_OBSCited in: Pathophysiology and Mechanism, Long-term and Definitive Management, Complications
  62. [62]

    Ribeiro VM, Cavalcante DN, Celkevicius HET et al.. “Lorundrostat for Patients With Uncontrolled Hypertension: A Systematic Review With Meta-Analysis and Trial Sequential Analysis.” American journal of hypertension (2026). PMID: 41428443 ↗

    L1SR_OBSCited in: Pathophysiology and Mechanism, Diagnosis and Workup, Long-term and Definitive Management, Renal Replacement Therapy, Transplantation and Electrolyte/Acid-Base Management, Complications
  63. [63]

    Abbasi M, Srivastava A, Saraf SL. “Management of Kidney Disease with Sickle Cell Disease.” Journal of the American Society of Nephrology : JASN (2025). PMID: 40569673 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism, Diagnosis and Workup, Complications, Prognosis and Natural History
  64. [64]

    Hattori K, Sakaguchi Y, Oka T et al.. “Estimated Effect of Restarting Renin-Angiotensin System Inhibitors after Discontinuation on Kidney Outcomes and Mortality.” Journal of the American Society of Nephrology : JASN (2024). PMID: 38889205 ↗

    L4OTHERCited in: Pathophysiology and Mechanism, Epidemiology, Etiology and Risk Factors, Diagnosis and Workup, Long-term and Definitive Management, Prognosis and Natural History, Special Populations and Prevention
  65. [65]

    Harris AN, Grimm PR, Lee HW et al.. “Mechanism of Hyperkalemia-Induced Metabolic Acidosis.” Journal of the American Society of Nephrology : JASN (2018). PMID: 29483157 ↗

    L4OTHERCited in: Pathophysiology and Mechanism, Diagnosis and Workup, Acute Management, Long-term and Definitive Management, Renal Replacement Therapy, Transplantation and Electrolyte/Acid-Base Management, Complications
  66. [66]

    Karet FE. “Mechanisms in hyperkalemic renal tubular acidosis.” Journal of the American Society of Nephrology : JASN (2009). PMID: 19193780 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism, Renal Replacement Therapy, Transplantation and Electrolyte/Acid-Base Management
  67. [67]

    de Groot T, Sinke AP, Kortenoeven ML et al.. “Acetazolamide Attenuates Lithium-Induced Nephrogenic Diabetes Insipidus.” Journal of the American Society of Nephrology : JASN (2015). PMID: 26574046 ↗

    L4OTHERCited in: Pathophysiology and Mechanism, Long-term and Definitive Management
  68. [68]

    Bullen AL, Ascher SB, Scherzer R et al.. “Markers of Kidney Tubular Secretion and Risk of Adverse Events in SPRINT Participants with CKD.” Journal of the American Society of Nephrology : JASN (2022). PMID: 35973732 ↗

    L3OTHERCited in: Pathophysiology and Mechanism, Epidemiology, Etiology and Risk Factors, Clinical Presentation, Diagnosis and Workup, Staging and Risk Stratification (KDIGO), Renal Replacement Therapy, Transplantation and Electrolyte/Acid-Base Management, Complications, Prognosis and Natural History
  69. [69]

    Wang J, Li X, Ke Y et al.. “GPR48 increases mineralocorticoid receptor gene expression.” Journal of the American Society of Nephrology : JASN (2011). PMID: 22135314 ↗

    L4OTHERCited in: Pathophysiology and Mechanism
  70. [70]

    Chen Z, Dong H, Jia C et al.. “Activation of mTORC1 in collecting ducts causes hyperkalemia.” Journal of the American Society of Nephrology : JASN (2013). PMID: 24203997 ↗

    L4OTHERCited in: Pathophysiology and Mechanism, Renal Replacement Therapy, Transplantation and Electrolyte/Acid-Base Management
  71. [71]

    Moranne O, Froissart M, Rossert J et al.. “Timing of onset of CKD-related metabolic complications.” Journal of the American Society of Nephrology : JASN (2008). PMID: 19005010 ↗

    L4OTHERCited in: Pathophysiology and Mechanism, Epidemiology, Etiology and Risk Factors, Diagnosis and Workup, Renal Replacement Therapy, Transplantation and Electrolyte/Acid-Base Management, Complications, Prognosis and Natural History, Special Populations and Prevention
  72. [72]

    Grimm PR, Coleman R, Delpire E et al.. “Constitutively Active SPAK Causes Hyperkalemia by Activating NCC and Remodeling Distal Tubules.” Journal of the American Society of Nephrology : JASN (2017). PMID: 28442491 ↗

    L4OTHERCited in: Pathophysiology and Mechanism, Long-term and Definitive Management
  73. [73]

    Chen J, Liu J, Xiao R et al.. “Efficacy of Vericiguat in Acute Heart Failure: A Target Trial Emulation Study.” Journal of the American Heart Association (2026). PMID: 41848038 ↗

    L4RCTCited in: Pathophysiology and Mechanism, Epidemiology, Etiology and Risk Factors, Clinical Presentation, Diagnosis and Workup, Long-term and Definitive Management, Complications, Special Populations and Prevention
  74. [74]

    Chimura M, Henderson AD, Jhund PS et al.. “Efficacy and Safety of the Kidney Function-Based Finerenone Dosing Strategy Used in FINEARTS-HF.” JACC. Heart failure (2026). PMID: 41642173 ↗

    L1RCTCited in: Pathophysiology and Mechanism, Diagnosis and Workup, Long-term and Definitive Management, Renal Replacement Therapy, Transplantation and Electrolyte/Acid-Base Management, Complications, Prognosis and Natural History, Special Populations and Prevention
  75. [75]

    Agarwal R, Green JB, Heerspink HJL et al.. “Risk of Hyperkalemia With Empagliflozin, Finerenone, or Both: Secondary Analysis of the CONFIDENCE Randomized Trial.” Journal of the American College of Cardiology (2025). PMID: 41493296 ↗

    L1RCTCited in: Pathophysiology and Mechanism, Epidemiology, Etiology and Risk Factors, Diagnosis and Workup, Staging and Risk Stratification (KDIGO), Long-term and Definitive Management, Renal Replacement Therapy, Transplantation and Electrolyte/Acid-Base Management, Prognosis and Natural History, Special Populations and Prevention
  76. [76]

    Banerjee D, Rosano G, Herzog CA. “Management of Heart Failure Patient with CKD.” Clinical journal of the American Society of Nephrology : CJASN (2021). PMID: 33495289 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism, Epidemiology, Etiology and Risk Factors, Long-term and Definitive Management, Renal Replacement Therapy, Transplantation and Electrolyte/Acid-Base Management, Complications
  77. [77]

    Spinowitz BS, Fishbane S, Pergola PE et al.. “Sodium Zirconium Cyclosilicate among Individuals with Hyperkalemia: A 12-Month Phase 3 Study.” Clinical journal of the American Society of Nephrology : CJASN (2019). PMID: 31110051 ↗

    L1OTHERCited in: Pathophysiology and Mechanism, Renal Replacement Therapy, Transplantation and Electrolyte/Acid-Base Management, Special Populations and Prevention
  78. [78]

    Palmer BF, Clegg DJ. “SGLT2 Inhibition and Kidney Potassium Homeostasis.” Clinical journal of the American Society of Nephrology : CJASN (2023). PMID: 37639260 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism, Long-term and Definitive Management, Renal Replacement Therapy, Transplantation and Electrolyte/Acid-Base Management
  79. [79]

    Weir MR, Rolfe M. “Potassium homeostasis and renin-angiotensin-aldosterone system inhibitors.” Clinical journal of the American Society of Nephrology : CJASN (2010). PMID: 20150448 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism, Epidemiology, Etiology and Risk Factors, Staging and Risk Stratification (KDIGO), Long-term and Definitive Management, Renal Replacement Therapy, Transplantation and Electrolyte/Acid-Base Management, Complications
  80. [80]

    Wilson FP, Berns JS. “Onco-nephrology: tumor lysis syndrome.” Clinical journal of the American Society of Nephrology : CJASN (2012). PMID: 22879434 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism, Epidemiology, Etiology and Risk Factors, Clinical Presentation, Diagnosis and Workup, Acute Management, Long-term and Definitive Management, Complications, Prognosis and Natural History
  81. [81]

    Turgut F, Balogun RA, Abdel-Rahman EM. “Renin-angiotensin-aldosterone system blockade effects on the kidney in the elderly: benefits and limitations.” Clinical journal of the American Society of Nephrology : CJASN (2010). PMID: 20498247 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism, Long-term and Definitive Management, Special Populations and Prevention
  82. [82]

    van den Belt SM, Heerspink HJL, Kirchner M et al.. “Discontinuation of RAAS Inhibition in Children with Advanced CKD.” Clinical journal of the American Society of Nephrology : CJASN (2020). PMID: 32253275 ↗

    L3OTHERCited in: Pathophysiology and Mechanism, Epidemiology, Etiology and Risk Factors, Clinical Presentation, Diagnosis and Workup, Staging and Risk Stratification (KDIGO), Long-term and Definitive Management, Complications, Prognosis and Natural History, Special Populations and Prevention
  83. [83]

    Hunter RW, Bailey MA. “Hyperkalemia: pathophysiology, risk factors and consequences.” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2019). PMID: 31800080 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism, Epidemiology, Etiology and Risk Factors, Diagnosis and Workup, Renal Replacement Therapy, Transplantation and Electrolyte/Acid-Base Management, Complications, Prognosis and Natural History
  84. [84]

    Georgianos PI, Agarwal R. “Hypertension in chronic kidney disease-treatment standard 2023.” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2023). PMID: 37355779 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism, Clinical Presentation, Diagnosis and Workup, Long-term and Definitive Management, Renal Replacement Therapy, Transplantation and Electrolyte/Acid-Base Management, Complications
  85. [85]

    Mutig K, Bachmann S. “Hyperkalemia and blood pressure regulation.” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2019). PMID: 31800077 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism, Renal Replacement Therapy, Transplantation and Electrolyte/Acid-Base Management, Complications
  86. [86]

    Chuang MH, Wang HY, Kan WC et al.. “Cardio-kidney outcomes for combined versus monotherapy with finerenone or SGLT2 inhibitors in patients with CKD.” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2025). PMID: 40199739 ↗

    L3OTHERCited in: Pathophysiology and Mechanism, Epidemiology, Etiology and Risk Factors, Diagnosis and Workup, Long-term and Definitive Management, Complications, Prognosis and Natural History, Special Populations and Prevention
  87. [87]

    Seliger SL. “Hyperkalemia in patients with chronic renal failure.” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2019). PMID: 31800076 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism, Epidemiology, Etiology and Risk Factors, Renal Replacement Therapy, Transplantation and Electrolyte/Acid-Base Management, Complications, Prognosis and Natural History
  88. [88]

    Wang AY. “Optimally managing hyperkalemia in patients with cardiorenal syndrome.” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2019). PMID: 31800079 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism, Epidemiology, Etiology and Risk Factors, Acute Management, Long-term and Definitive Management, Renal Replacement Therapy, Transplantation and Electrolyte/Acid-Base Management, Complications
  89. [89]

    Coutrot M, Dépret F, Legrand M. “Tailoring treatment of hyperkalemia.” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2019). PMID: 31800081 ↗

    L5OTHERCited in: Pathophysiology and Mechanism, Acute Management, Long-term and Definitive Management, Renal Replacement Therapy, Transplantation and Electrolyte/Acid-Base Management
  90. [90]

    Karam S, Rosner MH, Sprangers B et al.. “Cancer therapy in patients with reduced kidney function.” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2024). PMID: 38914465 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism, Diagnosis and Workup, Long-term and Definitive Management, Complications, Prognosis and Natural History
  91. [91]

    Guo Y, Zhao S, Dong Y et al.. “Efficacy and safety of finerenone with SGLT2i in IgA nephropathy.” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2026). PMID: 41206667 ↗

    L4OTHERCited in: Pathophysiology and Mechanism, Epidemiology, Etiology and Risk Factors, Clinical Presentation, Diagnosis and Workup, Long-term and Definitive Management, Renal Replacement Therapy, Transplantation and Electrolyte/Acid-Base Management, Prognosis and Natural History
  92. [92]

    Zietse R, Zoutendijk R, Hoorn EJ. “Fluid, electrolyte and acid-base disorders associated with antibiotic therapy.” Nature reviews. Nephrology (2009). PMID: 19322184 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism, Renal Replacement Therapy, Transplantation and Electrolyte/Acid-Base Management
  93. [93]

    Toto RD. “RAS blockade, hyperkalemia and AKI--look and you will find.” Nature reviews. Nephrology (2012). PMID: 22473512 ↗

    L5OTHERCited in: Pathophysiology and Mechanism, Epidemiology, Etiology and Risk Factors, Diagnosis and Workup, Long-term and Definitive Management, Renal Replacement Therapy, Transplantation and Electrolyte/Acid-Base Management, Prognosis and Natural History
  94. [94]

    Fishbane S, Dember LM, Jadoul M et al.. “The randomized DIALIZE-Outcomes trial evaluated sodium zirconium cyclosilicate in hemodialysis.” Kidney international (2025). PMID: 40618849 ↗

    L1RCTCited in: Epidemiology, Etiology and Risk Factors, Acute Management, Long-term and Definitive Management, Renal Replacement Therapy, Transplantation and Electrolyte/Acid-Base Management, Complications, Special Populations and Prevention
  95. [95]

    Charytan DM, Himmelfarb J, Ikizler TA et al.. “Safety and cardiovascular efficacy of spironolactone in dialysis-dependent ESRD (SPin-D): a randomized, placebo-controlled, multiple dosage trial.” Kidney international (2018). PMID: 30473139 ↗

    L1RCTCited in: Epidemiology, Etiology and Risk Factors, Clinical Presentation, Diagnosis and Workup, Acute Management, Long-term and Definitive Management, Complications, Prognosis and Natural History, Special Populations and Prevention
  96. [96]

    Hammer F, Malzahn U, Donhauser J et al.. “A randomized controlled trial of the effect of spironolactone on left ventricular mass in hemodialysis patients.” Kidney international (2019). PMID: 30712923 ↗

    L1RCTCited in: Epidemiology, Etiology and Risk Factors, Clinical Presentation, Diagnosis and Workup, Long-term and Definitive Management, Prognosis and Natural History, Special Populations and Prevention
  97. [97]

    Quach K, Lvtvyn L, Baigent C et al.. “The Safety and Efficacy of Mineralocorticoid Receptor Antagonists in Patients Who Require Dialysis: A Systematic Review and Meta-analysis.” American journal of kidney diseases : the official journal of the National Kidney Foundation (2016). PMID: 27265777 ↗

    L1SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Acute Management, Renal Replacement Therapy, Transplantation and Electrolyte/Acid-Base Management, Complications
  98. [98]

    Luo X, Xu J, Zhou S et al.. “Influence of SGLT2i and RAASi and Their Combination on Risk of Hyperkalemia in DKD: A Network Meta-Analysis.” Clinical journal of the American Society of Nephrology : CJASN (2023). PMID: 37256921 ↗

    L1SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Long-term and Definitive Management, Renal Replacement Therapy, Transplantation and Electrolyte/Acid-Base Management, Complications
  99. [99]

    Agarwal R, Joseph A, Anker SD et al.. “Hyperkalemia Risk with Finerenone: Results from the FIDELIO-DKD Trial.” Journal of the American Society of Nephrology : JASN (2021). PMID: 34732509 ↗

    L1RCTCited in: Epidemiology, Etiology and Risk Factors, Clinical Presentation, Diagnosis and Workup, Long-term and Definitive Management, Renal Replacement Therapy, Transplantation and Electrolyte/Acid-Base Management, Complications, Special Populations and Prevention
  100. [100]

    Fishbane S, Ford M, Fukagawa M et al.. “A Phase 3b, Randomized, Double-Blind, Placebo-Controlled Study of Sodium Zirconium Cyclosilicate for Reducing the Incidence of Predialysis Hyperkalemia.” Journal of the American Society of Nephrology : JASN (2019). PMID: 31201218 ↗

    L1RCTCited in: Epidemiology, Etiology and Risk Factors, Acute Management, Long-term and Definitive Management, Renal Replacement Therapy, Transplantation and Electrolyte/Acid-Base Management, Complications, Prognosis and Natural History, Special Populations and Prevention
  101. [101]

    McMurray JJ, Packer M, Desai AS et al.. “Angiotensin-neprilysin inhibition versus enalapril in heart failure.” The New England journal of medicine (2014). PMID: 25176015 ↗

    L1RCTCited in: Epidemiology, Etiology and Risk Factors, Long-term and Definitive Management, Complications, Prognosis and Natural History, Special Populations and Prevention
  102. [102]

    Pitt B, Filippatos G, Agarwal R et al.. “Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes.” The New England journal of medicine (2021). PMID: 34449181 ↗

    L1RCTCited in: Epidemiology, Etiology and Risk Factors, Clinical Presentation, Diagnosis and Workup, Staging and Risk Stratification (KDIGO), Long-term and Definitive Management, Complications, Special Populations and Prevention
  103. [103]

    Neal B, Wu Y, Feng X et al.. “Effect of Salt Substitution on Cardiovascular Events and Death.” The New England journal of medicine (2021). PMID: 34459569 ↗

    L1RCTCited in: Epidemiology, Etiology and Risk Factors, Long-term and Definitive Management, Renal Replacement Therapy, Transplantation and Electrolyte/Acid-Base Management
  104. [104]

    Parving HH, Brenner BM, McMurray JJ et al.. “Cardiorenal end points in a trial of aliskiren for type 2 diabetes.” The New England journal of medicine (2012). PMID: 23121378 ↗

    L1RCTCited in: Epidemiology, Etiology and Risk Factors, Acute Management, Renal Replacement Therapy, Transplantation and Electrolyte/Acid-Base Management
  105. [105]

    Hwang YJ, Muanda FT, McArthur E et al.. “Trimethoprim-sulfamethoxazole and the risk of a hospital encounter with hyperkalemia: a matched population-based cohort study.” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2023). PMID: 36208171 ↗

    L2COHORTCited in: Epidemiology, Etiology and Risk Factors
  106. [106]

    Thomsen RW, Nicolaisen SK, Hasvold P et al.. “Elevated potassium levels in patients with chronic kidney disease: occurrence, risk factors and clinical outcomes-a Danish population-based cohort study.” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2018). PMID: 29177463 ↗

    L2COHORTCited in: Epidemiology, Etiology and Risk Factors, Staging and Risk Stratification (KDIGO), Prognosis and Natural History, Special Populations and Prevention
  107. [107]

    Lafrance JP, Miller DR. “Dispensed selective and nonselective nonsteroidal anti-inflammatory drugs and the risk of moderate to severe hyperkalemia: a nested case-control study.” American journal of kidney diseases : the official journal of the National Kidney Foundation (2012). PMID: 22503390 ↗

    L3CASE_CONTROLCited in: Epidemiology, Etiology and Risk Factors, Clinical Presentation, Diagnosis and Workup, Special Populations and Prevention
  108. [108]

    Al-Sagban A, Algodi M, Saab O et al.. “Lung ultrasound-guided decongestion in heart failure patients: A systematic review and meta-analysis of randomized controlled trials.” Journal of critical care (2026). PMID: 41643462 ↗

    L1SR_MA_RCTCited in: Epidemiology, Etiology and Risk Factors, Clinical Presentation, Diagnosis and Workup, Acute Management, Complications
  109. [109]

    Barrera-Chimal J, Girerd S, Jaisser F. “Mineralocorticoid receptor antagonists and kidney diseases: pathophysiological basis.” Kidney international (2019). PMID: 31133455 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology, Etiology and Risk Factors, Acute Management, Long-term and Definitive Management, Complications, Prognosis and Natural History
  110. [110]

    Fu EL, Mastrorilli J, Bykov K et al.. “A population-based cohort defined risk of hyperkalemia after initiating SGLT-2 inhibitors, GLP1 receptor agonists or DPP-4 inhibitors to patients with chronic kidney disease and type 2 diabetes.” Kidney international (2023). PMID: 38101515 ↗

    L2OTHERCited in: Epidemiology, Etiology and Risk Factors, Acute Management, Long-term and Definitive Management, Renal Replacement Therapy, Transplantation and Electrolyte/Acid-Base Management, Complications
  111. [111]

    Karaboyas A, Xu H, Morgenstern H et al.. “DOPPS data suggest a possible survival benefit of renin angiotensin-aldosterone system inhibitors and other antihypertensive medications for hemodialysis patients.” Kidney international (2018). PMID: 29908836 ↗

    L2OTHERCited in: Epidemiology, Etiology and Risk Factors
  112. [112]

    Fried L, Kovesdy CP, Palmer BF. “New options for the management of chronic hyperkalemia.” Kidney international supplements (2017). PMID: 30675431 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology, Etiology and Risk Factors
  113. [113]

    Kim TY, Ahn GJ, Cha KC et al.. “2025 Korean Guidelines for Cardiopulmonary Resuscitation: Part 5. Cardiac arrest in special circumstances.” Clinical and experimental emergency medicine (2026). PMID: 42297408 ↗

    L1GUIDELINECited in: Epidemiology, Etiology and Risk Factors, Acute Management
  114. [114]

    Abu-Alfa AK, Younes A. “Tumor lysis syndrome and acute kidney injury: evaluation, prevention, and management.” American journal of kidney diseases : the official journal of the National Kidney Foundation (2010). PMID: 20420966 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology, Etiology and Risk Factors, Complications
  115. [115]

    de Rooij ENM, de Fijter JW, Le Cessie S et al.. “Serum Potassium and Risk of Death or Kidney Replacement Therapy in Older People With CKD Stages 4-5: Eight-Year Follow-up.” American journal of kidney diseases : the official journal of the National Kidney Foundation (2023). PMID: 37182596 ↗

    L2OTHERCited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup, Long-term and Definitive Management, Renal Replacement Therapy, Transplantation and Electrolyte/Acid-Base Management, Prognosis and Natural History, Special Populations and Prevention
  116. [116]

    Chen Y, Sang Y, Ballew SH et al.. “Race, Serum Potassium, and Associations With ESRD and Mortality.” American journal of kidney diseases : the official journal of the National Kidney Foundation (2017). PMID: 28363732 ↗

    L2OTHERCited in: Epidemiology, Etiology and Risk Factors, Prognosis and Natural History
  117. [117]

    Thomas A, Silver SA, Perl J et al.. “The Frequency of Routine Blood Sampling and Patient Outcomes Among Maintenance Hemodialysis Recipients.” American journal of kidney diseases : the official journal of the National Kidney Foundation (2019). PMID: 31732233 ↗

    L2OTHERCited in: Epidemiology, Etiology and Risk Factors, Acute Management, Special Populations and Prevention
  118. [118]

    Hsu KL, Fink JC, Ginsberg JS et al.. “Self-reported Medication Adherence and Adverse Patient Safety Events in CKD.” American journal of kidney diseases : the official journal of the National Kidney Foundation (2015). PMID: 25979348 ↗

    L4OTHERCited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup, Staging and Risk Stratification (KDIGO), Prognosis and Natural History
  119. [119]

    Tear AA, Fauziah N, Riswari SF et al.. “Prognostic factors in malaria patients with acute kidney injury: a systematic review and meta analysis.” Renal failure (2026). PMID: 42185742 ↗

    L2SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Clinical Presentation, Renal Replacement Therapy, Transplantation and Electrolyte/Acid-Base Management, Complications
  120. [120]

    Zhu Y, Li J, Huang Z et al.. “Mineralocorticoid receptor antagonists in dialysis patients after ACHIEVE and ALCHEMIST: updated systematic review and meta-analysis of 14 randomized trials.” Renal failure (2026). PMID: 42056760 ↗

    L1SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Acute Management, Renal Replacement Therapy, Transplantation and Electrolyte/Acid-Base Management, Complications, Prognosis and Natural History
  121. [121]

    Riaz AA, Abrar Z, Cheema FF et al.. “Safety and efficacy of novel potassium binders for chronic hyperkalemia: a systematic review and meta-analysis of randomized controlled trials.” Proceedings (Baylor University. Medical Center) (2025). PMID: 41487544 ↗

    L1SR_MA_RCTCited in: Epidemiology, Etiology and Risk Factors
  122. [122]

    Montford JR, Linas S. “How Dangerous Is Hyperkalemia?” Journal of the American Society of Nephrology : JASN (2017). PMID: 28778861 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology, Etiology and Risk Factors, Clinical Presentation, Acute Management, Renal Replacement Therapy, Transplantation and Electrolyte/Acid-Base Management, Complications
  123. [123]

    Ruggenenti P, Perticucci E, Cravedi P et al.. “Role of remission clinics in the longitudinal treatment of CKD.” Journal of the American Society of Nephrology : JASN (2008). PMID: 18354029 ↗

    L2OTHERCited in: Epidemiology, Etiology and Risk Factors, Clinical Presentation, Diagnosis and Workup, Long-term and Definitive Management, Prognosis and Natural History
  124. [124]

    Ginsberg JS, Zhan M, Diamantidis CJ et al.. “Patient-reported and actionable safety events in CKD.” Journal of the American Society of Nephrology : JASN (2014). PMID: 24556352 ↗

    L4OTHERCited in: Epidemiology, Etiology and Risk Factors, Complications, Special Populations and Prevention
  125. [125]

    Geller DS, Zhang J, Zennaro MC et al.. “Autosomal dominant pseudohypoaldosteronism type 1: mechanisms, evidence for neonatal lethality, and phenotypic expression in adults.” Journal of the American Society of Nephrology : JASN (2006). PMID: 16611713 ↗

    L4OTHERCited in: Epidemiology, Etiology and Risk Factors, Staging and Risk Stratification (KDIGO)
  126. [126]

    Deng Z, Fu W, Chen F et al.. “Association between low-dose trimethoprim-sulfamethoxazole blood concentration and clinical outcomes in non-HIV patients with Pneumocystis jirovecii pneumonia: a retrospective cohort study.” BMC infectious diseases (2026). PMID: 41772486 ↗

    L3COHORTCited in: Epidemiology, Etiology and Risk Factors
  127. [127]

    Gregoire S, Dewey E, Sanchez K et al.. “Hyperkalemia incidence in females over 45 years old on spironolactone for dermatologic conditions: A retrospective cohort study.” Journal of the American Academy of Dermatology (2026). PMID: 41655839 ↗

    L3COHORTCited in: Epidemiology, Etiology and Risk Factors, Renal Replacement Therapy, Transplantation and Electrolyte/Acid-Base Management, Special Populations and Prevention
  128. [128]

    Hu Y, Hu W, Li D et al.. “Reassessing the efficacy and safety of trimethoprim-sulfamethoxazole for Pneumocystis jirovecii pneumonia: a retrospective study.” European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology (2026). PMID: 41563564 ↗

    L3COHORTCited in: Epidemiology, Etiology and Risk Factors
  129. [129]

    Idemitsu R, Nagai T, Matsui H et al.. “Risk factors for adverse events associated with trimethoprim-sulfamethoxazole treatment for Pneumocystis pneumonia in non-human immunodeficiency virus-infected patients: a multicenter, retrospective, observational cohort study.” BMC infectious diseases (2026). PMID: 41559609 ↗

    L3COHORTCited in: Epidemiology, Etiology and Risk Factors
  130. [130]

    Bernier-Jean A, Wong G, Saglimbene V et al.. “Dietary Potassium Intake and All-Cause Mortality in Adults Treated with Hemodialysis.” Clinical journal of the American Society of Nephrology : CJASN (2021). PMID: 34853064 ↗

    L3OTHERCited in: Epidemiology, Etiology and Risk Factors, Acute Management, Renal Replacement Therapy, Transplantation and Electrolyte/Acid-Base Management, Complications, Prognosis and Natural History
  131. [131]

    Kliger AS. “Maintaining safety in the dialysis facility.” Clinical journal of the American Society of Nephrology : CJASN (2014). PMID: 25376767 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology, Etiology and Risk Factors, Staging and Risk Stratification (KDIGO), Acute Management, Renal Replacement Therapy, Transplantation and Electrolyte/Acid-Base Management
  132. [132]

    Hundemer GL, Talarico R, Tangri N et al.. “Ambulatory Treatments for RAAS Inhibitor-Related Hyperkalemia and the 1-Year Risk of Recurrence.” Clinical journal of the American Society of Nephrology : CJASN (2021). PMID: 33608262 ↗

    L3OTHERCited in: Epidemiology, Etiology and Risk Factors, Staging and Risk Stratification (KDIGO), Acute Management, Special Populations and Prevention
  133. [133]

    Rossing P, Birkenfeld AL, Fioretto P et al.. “Finerenone and Clinical Outcomes in CKD and Type 2 Diabetes by Frailty Index: FIDELITY Post Hoc Analysis.” Clinical journal of the American Society of Nephrology : CJASN (2025). PMID: 40315020 ↗

    L3OTHERCited in: Epidemiology, Etiology and Risk Factors
  134. [134]

    Avesani CM, Cecchini V, Sabatino A et al.. “Ultra-Processed Foods and Food Additives in CKD: Unveiling Hidden Risks and Advocating Smarter Food Choices.” Clinical journal of the American Society of Nephrology : CJASN (2025). PMID: 40512553 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology, Etiology and Risk Factors
  135. [135]

    Sarafidis PA, Blacklock R, Wood E et al.. “Prevalence and factors associated with hyperkalemia in predialysis patients followed in a low-clearance clinic.” Clinical journal of the American Society of Nephrology : CJASN (2012). PMID: 22595825 ↗

    L4OTHERCited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup
  136. [136]

    Bosi A, Xu Y, Faucon AL et al.. “Hyperkalemia and maintenance of renin-angiotensin system inhibitor therapy after initiating SGLT-2 or DPP-4 inhibitors.” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2025). PMID: 39384578 ↗

    L3OTHERCited in: Epidemiology, Etiology and Risk Factors, Special Populations and Prevention
  137. [137]

    Wetmore JB, Yan H, Horne L et al.. “Risk of hyperkalemia from renin-angiotensin-aldosterone system inhibitors and factors associated with treatment discontinuities in a real-world population.” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2021). PMID: 31846025 ↗

    L3OTHERCited in: Epidemiology, Etiology and Risk Factors, Special Populations and Prevention
  138. [138]

    Seethapathy H, Rusibamayila N, Chute DF et al.. “Hyponatremia and other electrolyte abnormalities in patients receiving immune checkpoint inhibitors.” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2021). PMID: 33374011 ↗

    L3OTHERCited in: Epidemiology, Etiology and Risk Factors
  139. [139]

    Charytan DM, Winkelmayer WC, Granger CB et al.. “Effects of dialysate potassium concentration of 3.0 mmol/l with sodium zirconium cyclosilicate on dialysis-free days versus dialysate potassium concentration of 2.0 mmol/l alone on rates of cardiac arrhythmias in hemodialysis patients with hyperkalemia.” Kidney international (2024). PMID: 39490411 ↗

    L1RCTCited in: Clinical Presentation, Diagnosis and Workup, Acute Management, Long-term and Definitive Management, Renal Replacement Therapy, Transplantation and Electrolyte/Acid-Base Management, Complications, Special Populations and Prevention
  140. [140]

    Ash SR, Singh B, Lavin PT et al.. “A phase 2 study on the treatment of hyperkalemia in patients with chronic kidney disease suggests that the selective potassium trap, ZS-9, is safe and efficient.” Kidney international (2015). PMID: 25651363 ↗

    L1RCTCited in: Clinical Presentation, Special Populations and Prevention
  141. [141]

    Bianchi S, Bigazzi R, Campese VM. “Intensive versus conventional therapy to slow the progression of idiopathic glomerular diseases.” American journal of kidney diseases : the official journal of the National Kidney Foundation (2010). PMID: 20097461 ↗

    L1RCTCited in: Clinical Presentation, Diagnosis and Workup, Prognosis and Natural History
  142. [142]

    Navaneethan SD, Nigwekar SU, Sehgal AR et al.. “Aldosterone antagonists for preventing the progression of chronic kidney disease: a systematic review and meta-analysis.” Clinical journal of the American Society of Nephrology : CJASN (2009). PMID: 19261819 ↗

    L1SR_OBSCited in: Clinical Presentation, Diagnosis and Workup, Staging and Risk Stratification (KDIGO), Long-term and Definitive Management, Renal Replacement Therapy, Transplantation and Electrolyte/Acid-Base Management, Complications, Prognosis and Natural History
  143. [143]

    Velazquez EJ, Morrow DA, DeVore AD et al.. “Angiotensin-Neprilysin Inhibition in Acute Decompensated Heart Failure.” The New England journal of medicine (2018). PMID: 30415601 ↗

    L1RCTCited in: Clinical Presentation, Long-term and Definitive Management, Complications, Special Populations and Prevention
  144. [144]

    Lepage L, Dufour AC, Doiron J et al.. “Randomized Clinical Trial of Sodium Polystyrene Sulfonate for the Treatment of Mild Hyperkalemia in CKD.” Clinical journal of the American Society of Nephrology : CJASN (2015). PMID: 26576619 ↗

    L1RCTCited in: Clinical Presentation, Long-term and Definitive Management
  145. [145]

    Ito S, Shikata K, Nangaku M et al.. “Efficacy and Safety of Esaxerenone (CS-3150) for the Treatment of Type 2 Diabetes with Microalbuminuria: A Randomized, Double-Blind, Placebo-Controlled, Phase II Trial.” Clinical journal of the American Society of Nephrology : CJASN (2019). PMID: 31248950 ↗

    L1RCTCited in: Clinical Presentation, Staging and Risk Stratification (KDIGO)
  146. [146]

    Edwards NC, Price AM, Mehta S et al.. “Effects of Spironolactone and Chlorthalidone on Cardiovascular Structure and Function in Chronic Kidney Disease: A Randomized, Open-Label Trial.” Clinical journal of the American Society of Nephrology : CJASN (2021). PMID: 34462286 ↗

    L1RCTCited in: Clinical Presentation, Diagnosis and Workup, Prognosis and Natural History, Special Populations and Prevention
  147. [147]

    Epstein M, Williams GH, Weinberger M et al.. “Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes.” Clinical journal of the American Society of Nephrology : CJASN (2006). PMID: 17699311 ↗

    L1RCTCited in: Clinical Presentation
  148. [148]

    Esteghamati A, Noshad S, Jarrah S et al.. “Long-term effects of addition of mineralocorticoid receptor antagonist to angiotensin II receptor blocker in patients with diabetic nephropathy: a randomized clinical trial.” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2013). PMID: 24009294 ↗

    L1RCTCited in: Clinical Presentation
  149. [149]

    Ascher SB, Scherzer R, Estrella MM et al.. “Kidney tubule health, mineral metabolism and adverse events in persons with CKD in SPRINT.” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2022). PMID: 34473302 ↗

    L3TRIAL_NONRANDOMCited in: Clinical Presentation, Diagnosis and Workup, Staging and Risk Stratification (KDIGO), Complications, Prognosis and Natural History, Special Populations and Prevention
  150. [150]

    Tang SC, Lin M, Tam S et al.. “Aliskiren combined with losartan in immunoglobulin A nephropathy: an open-labeled pilot study.” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2011). PMID: 21680850 ↗

    L4TRIAL_NONRANDOMCited in: Clinical Presentation, Diagnosis and Workup, Staging and Risk Stratification (KDIGO)
  151. [151]

    Cai J, Huang X, Zheng Z et al.. “Comparative efficacy of individual renin-angiotensin system inhibitors on major renal outcomes in diabetic kidney disease: a network meta-analysis.” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2018). PMID: 29579289 ↗

    L1SR_OBSCited in: Clinical Presentation, Staging and Risk Stratification (KDIGO)
  152. [152]

    Leclerc S, Royal V, Lamarche C et al.. “Minimal Change Disease With Severe Acute Kidney Injury Following the Oxford-AstraZeneca COVID-19 Vaccine: A Case Report.” American journal of kidney diseases : the official journal of the National Kidney Foundation (2021). PMID: 34242687 ↗

    L4CASE_REPORTCited in: Clinical Presentation, Diagnosis and Workup, Staging and Risk Stratification (KDIGO), Special Populations and Prevention
  153. [153]

    Shingarev R, Allon M. “A physiologic-based approach to the treatment of acute hyperkalemia.” American journal of kidney diseases : the official journal of the National Kidney Foundation (2010). PMID: 20570423 ↗

    L5CASE_REPORTCited in: Clinical Presentation, Special Populations and Prevention
  154. [154]

    Vigneau C, Daugas E, Maury E et al.. “Renal cortical necrosis related to paraneoplastic antiphospholipid syndrome.” American journal of kidney diseases : the official journal of the National Kidney Foundation (2006). PMID: 16731303 ↗

    L4CASE_REPORTCited in: Clinical Presentation, Diagnosis and Workup
  155. [155]

    Kim JO, Kim GH, Kang CM et al.. “Bilateral acute renal cortical necrosis in SLE-associated antiphospholipid syndrome.” American journal of kidney diseases : the official journal of the National Kidney Foundation (2011). PMID: 21514023 ↗

    L4CASE_REPORTCited in: Clinical Presentation
  156. [156]

    Bakris GL, Ruilope LM, Anker SD et al.. “A prespecified exploratory analysis from FIDELITY examined finerenone use and kidney outcomes in patients with chronic kidney disease and type 2 diabetes.” Kidney international (2022). PMID: 36367466 ↗

    L1OTHERCited in: Clinical Presentation, Diagnosis and Workup, Long-term and Definitive Management, Complications, Prognosis and Natural History
  157. [157]

    Sterns RH, Grieff M, Bernstein PL. “Treatment of hyperkalemia: something old, something new.” Kidney international (2016). PMID: 26880451 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation, Diagnosis and Workup, Acute Management, Long-term and Definitive Management, Renal Replacement Therapy, Transplantation and Electrolyte/Acid-Base Management
  158. [158]

    Bagchi S, Husain Zaidi S, Prasad Mathur R. “Severe symptomatic hyponatremia--an uncommon presentation of tacrolimus nephrotoxicity.” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2011). PMID: 21454354 ↗

    L4CASE_REPORTCited in: Clinical Presentation
  159. [159]

    Li SG, Long T, Yu R et al.. “Adrenal involvement in antiphospholipid syndrome and SLE-spectrum disease: a systematic review and pooled individual-patient analysis.” Frontiers in immunology (2026). PMID: 42317308 ↗

    L3SR_OBSCited in: Clinical Presentation, Complications
  160. [160]

    Cohen DL, Townsend RR. “Is there added value to adding ARB to ACE inhibitors in the management of CKD?” Journal of the American Society of Nephrology : JASN (2008). PMID: 18776118 ↗

    L5OTHERCited in: Clinical Presentation, Diagnosis and Workup
  161. [161]

    Harmon DM, Liu K, Dugan J et al.. “Validation of Noninvasive Detection of Hyperkalemia by Artificial Intelligence-Enhanced Electrocardiography in High Acuity Settings.” Clinical journal of the American Society of Nephrology : CJASN (2024). PMID: 39116276 ↗

    L3OTHERCited in: Clinical Presentation, Diagnosis and Workup
  162. [162]

    Palmer BF, Clegg DJ. “Hyperkalemia treatment standard.” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2024). PMID: 38425037 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation, Diagnosis and Workup, Acute Management, Renal Replacement Therapy, Transplantation and Electrolyte/Acid-Base Management
  163. [163]

    Pérez-Mir M, Canal Girol C, Escolà-Vergé L et al.. “Antibiotic Tolerability in Nocardia Infection Among Kidney Transplant Recipients: A Multicenter Cohort Study.” Transplant infectious disease : an official journal of the Transplantation Society (2026). PMID: 42142207 ↗

    L3COHORTCited in: Clinical Presentation
  164. [164]

    Wathanavasin W, Jaturapisanukul S, Thongprayoon C et al.. “Efficacy and Tolerability of Sodium Zirconium Cyclosilicate or Patiromer in Managing Hyperkalemia: A Systematic Review and Meta-Analysis.” Kidney360 (2026). PMID: 41811379 ↗

    L1SR_OBSCited in: Clinical Presentation
  165. [165]

    Better OS, Abassi ZA. “Early fluid resuscitation in patients with rhabdomyolysis.” Nature reviews. Nephrology (2011). PMID: 21587227 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation, Acute Management, Complications
  166. [166]

    Chen K, Shao W, Zhang H. “Meta-analysis of the efficacy and safety of Finerenone in diabetic kidney disease.” Medicine (2026). PMID: 41578591 ↗

    L1SR_OBSCited in: Clinical Presentation
  167. [167]

    Zhang R, Zhang Y, Nie Y et al.. “Coexistence of 21-hydroxylase deficiency and Gitelman syndrome in a neonate presenting with severe hyponatremic seizures: a case report.” Frontiers in endocrinology (2026). PMID: 42358677 ↗

    L4CASE_REPORTCited in: Clinical Presentation, Renal Replacement Therapy, Transplantation and Electrolyte/Acid-Base Management
  168. [168]

    Morrissey B. “Acute urinary retention presenting as inferior pseudo-STEMI: A case report.” The American journal of emergency medicine (2026). PMID: 42330710 ↗

    L4CASE_REPORTCited in: Clinical Presentation
  169. [169]

    Bushinsky DA, Spiegel DM, Yuan J et al.. “Effects of the Potassium-Binding Polymer Patiromer on Markers of Mineral Metabolism.” Clinical journal of the American Society of Nephrology : CJASN (2018). PMID: 30381412 ↗

    L1RCTCited in: Diagnosis and Workup, Prognosis and Natural History, Special Populations and Prevention
  170. [170]

    Tang SCW, Chan KW, Ip DKM et al.. “Direct Renin Inhibition in Non-diabetic chronic Kidney disease (DRINK): a prospective randomized trial.” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2021). PMID: 32617578 ↗

    L1RCTCited in: Diagnosis and Workup, Complications, Prognosis and Natural History, Special Populations and Prevention
  171. [171]

    Hsu CY, Propert K, Xie D et al.. “Measured GFR does not outperform estimated GFR in predicting CKD-related complications.” Journal of the American Society of Nephrology : JASN (2011). PMID: 21921144 ↗

    L2TRIAL_NONRANDOMCited in: Diagnosis and Workup, Prognosis and Natural History, Special Populations and Prevention
  172. [172]

    Palmer BF. “A physiologic-based approach to the evaluation of a patient with hyperkalemia.” American journal of kidney diseases : the official journal of the National Kidney Foundation (2010). PMID: 20493606 ↗

    L5CASE_REPORTCited in: Diagnosis and Workup
  173. [173]

    Butler MJ, Ramnath R, Kadoya H et al.. “Aldosterone induces albuminuria via matrix metalloproteinase-dependent damage of the endothelial glycocalyx.” Kidney international (2018). PMID: 30389198 ↗

    L5OTHERCited in: Diagnosis and Workup, Staging and Risk Stratification (KDIGO)
  174. [174]

    Tsutsumi YM, Nagasaka H, Mukaida K et al.. “JSA guideline for management of malignant hyperthermia in 2025.” Journal of anesthesia (2026). PMID: 41504952 ↗

    L1GUIDELINECited in: Diagnosis and Workup
  175. [175]

    Diamantidis CJ, Seliger SL, Zhan M et al.. “A varying patient safety profile between black and nonblack adults with decreased estimated GFR.” American journal of kidney diseases : the official journal of the National Kidney Foundation (2012). PMID: 22483674 ↗

    L3OTHERCited in: Diagnosis and Workup
  176. [176]

    Liu BC, Yang LL, Lu XY et al.. “Lovastatin-Induced Phosphatidylinositol-4-Phosphate 5-Kinase Diffusion from Microvilli Stimulates ROMK Channels.” Journal of the American Society of Nephrology : JASN (2014). PMID: 25349201 ↗

    L5OTHERCited in: Diagnosis and Workup
  177. [177]

    Wu CR, Chang YC, Tranyor V et al.. “Machine learning-based prediction of delirium in older patients with chronic kidney disease requiring intensive care: A hospital-based retrospective cohort study.” Journal of psychosomatic research (2025). PMID: 41265364 ↗

    L3COHORTCited in: Diagnosis and Workup
  178. [178]

    Liu X, Lin Q, Gao K et al.. “Association between serum potassium and 28-day mortality in elderly patients with sepsis: a multicenter cohort study.” BMC geriatrics (2025). PMID: 41225362 ↗

    L3COHORTCited in: Diagnosis and Workup
  179. [179]

    Luo J, Brunelli SM, Jensen DE et al.. “Association between Serum Potassium and Outcomes in Patients with Reduced Kidney Function.” Clinical journal of the American Society of Nephrology : CJASN (2015). PMID: 26500246 ↗

    L3OTHERCited in: Diagnosis and Workup
  180. [180]

    Ronksley PE, Hemmelgarn BR, Manns BJ et al.. “Potentially Preventable Hospitalization among Patients with CKD and High Inpatient Use.” Clinical journal of the American Society of Nephrology : CJASN (2016). PMID: 27821636 ↗

    L3OTHERCited in: Diagnosis and Workup
  181. [181]

    Hughes-Austin JM, Rifkin DE, Beben T et al.. “The Relation of Serum Potassium Concentration with Cardiovascular Events and Mortality in Community-Living Individuals.” Clinical journal of the American Society of Nephrology : CJASN (2017). PMID: 28143865 ↗

    L3OTHERCited in: Diagnosis and Workup
  182. [182]

    Libório AB, Leite TT, Neves FM et al.. “AKI complications in critically ill patients: association with mortality rates and RRT.” Clinical journal of the American Society of Nephrology : CJASN (2014). PMID: 25376761 ↗

    L3OTHERCited in: Diagnosis and Workup
  183. [183]

    Raza SA, Rehman AU, Aamir AH et al.. “Comparative efficacy and safety of finerenone in diabetic kidney disease: a meta-analysis of Asian and non-Asian populations.” BMC nephrology (2025). PMID: 41272492 ↗

    L1SR_OBSCited in: Diagnosis and Workup, Long-term and Definitive Management
  184. [184]

    Granal M, Fouque D, Ducher M et al.. “Factors associated with kalemia in renal disease.” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2023). PMID: 36662047 ↗

    L3OTHERCited in: Diagnosis and Workup, Renal Replacement Therapy, Transplantation and Electrolyte/Acid-Base Management, Complications, Prognosis and Natural History
  185. [185]

    Gritter M, Wei KY, Wouda RD et al.. “Chronic kidney disease increases the susceptibility to negative effects of low and high potassium intake.” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2024). PMID: 37813819 ↗

    L4OTHERCited in: Diagnosis and Workup, Prognosis and Natural History
  186. [186]

    Nash DM, Markle-Reid M, Brimble KS et al.. “Nonsteroidal anti-inflammatory drug use and risk of acute kidney injury and hyperkalemia in older adults: a population-based study.” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2019). PMID: 31264694 ↗

    L3OTHERCited in: Diagnosis and Workup, Staging and Risk Stratification (KDIGO), Special Populations and Prevention
  187. [187]

    Okparavero A, Foster MC, Tighiouart H et al.. “Prevalence and complications of chronic kidney disease in a representative elderly population in Iceland.” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2015). PMID: 26519958 ↗

    L2OTHERCited in: Diagnosis and Workup
  188. [188]

    Martinez Y, Vilches M, Gil S et al.. “Incidence and predictors of hyperkalemia after subtotal parathyroidectomy in pediatric chronic dialysis patients with secondary hyperparathyroidism: a retrospective cohort study.” BMC nephrology (2025). PMID: 41146065 ↗

    L4COHORTCited in: Diagnosis and Workup, Acute Management
  189. [189]

    Katayama S, Anker SD, Zhu D et al.. “Efficacy and safety of finerenone in Asian patients with type 2 diabetes and chronic kidney disease: A FIDELITY analysis by baseline kidney function.” Journal of diabetes and its complications (2025). PMID: 41289823 ↗

    L1RCTCited in: Diagnosis and Workup, Long-term and Definitive Management
  190. [190]

    Cheung AK, Chang TI, Cushman WC et al.. “Executive summary of the KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease.” Kidney international (2021). PMID: 33637203 ↗

    L1GUIDELINECited in: Staging and Risk Stratification (KDIGO), Acute Management, Long-term and Definitive Management, Renal Replacement Therapy, Transplantation and Electrolyte/Acid-Base Management, Special Populations and Prevention
  191. [191]

    Korgaonkar S, Tilea A, Gillespie BW et al.. “Serum potassium and outcomes in CKD: insights from the RRI-CKD cohort study.” Clinical journal of the American Society of Nephrology : CJASN (2010). PMID: 20203167 ↗

    L2COHORTCited in: Staging and Risk Stratification (KDIGO)
  192. [192]

    Weir MA, Juurlink DN, Gomes T et al.. “Beta-blockers, trimethoprim-sulfamethoxazole, and the risk of hyperkalemia requiring hospitalization in the elderly: a nested case-control study.” Clinical journal of the American Society of Nephrology : CJASN (2010). PMID: 20595693 ↗

    L3CASE_CONTROLCited in: Staging and Risk Stratification (KDIGO)
  193. [193]

    Shen JI, Winkelmayer WC. “Use and safety of unfractionated heparin for anticoagulation during maintenance hemodialysis.” American journal of kidney diseases : the official journal of the National Kidney Foundation (2012). PMID: 22560830 ↗

    L5CASE_REPORTCited in: Staging and Risk Stratification (KDIGO), Acute Management, Renal Replacement Therapy, Transplantation and Electrolyte/Acid-Base Management, Prognosis and Natural History
  194. [194]

    Seimiya M, Yoshida T, Sawabe Y et al.. “Reducing the incidence of pseudohyperkalemia by avoiding making a fist during phlebotomy: a quality improvement report.” American journal of kidney diseases : the official journal of the National Kidney Foundation (2010). PMID: 20801569 ↗

    L4OTHERCited in: Staging and Risk Stratification (KDIGO)
  195. [195]

    Brunelli SM, Du Mond C, Oestreicher N et al.. “Serum Potassium and Short-term Clinical Outcomes Among Hemodialysis Patients: Impact of the Long Interdialytic Interval.” American journal of kidney diseases : the official journal of the National Kidney Foundation (2017). PMID: 28111027 ↗

    L3OTHERCited in: Staging and Risk Stratification (KDIGO), Acute Management
  196. [196]

    Roy P, Bouchard J, Amyot R et al.. “Prescription patterns of pharmacological agents for left ventricular systolic dysfunction among hemodialysis patients.” American journal of kidney diseases : the official journal of the National Kidney Foundation (2006). PMID: 16997061 ↗

    L4OTHERCited in: Staging and Risk Stratification (KDIGO), Acute Management
  197. [197]

    Karaboyas A, Zee J, Brunelli SM et al.. “Dialysate Potassium, Serum Potassium, Mortality, and Arrhythmia Events in Hemodialysis: Results From the Dialysis Outcomes and Practice Patterns Study (DOPPS).” American journal of kidney diseases : the official journal of the National Kidney Foundation (2016). PMID: 27866964 ↗

    L2OTHERCited in: Staging and Risk Stratification (KDIGO), Acute Management
  198. [198]

    Yuan CY, Gao YC, Lin Y et al.. “Effects of Mineralocorticoid Receptor Antagonists for Chronic Kidney Disease: A Systemic Review and Meta-Analysis.” American journal of nephrology (2023). PMID: 37793348 ↗

    L1SR_OBSCited in: Staging and Risk Stratification (KDIGO)
  199. [199]

    Perrier R, Boscardin E, Malsure S et al.. “Severe Salt-Losing Syndrome and Hyperkalemia Induced by Adult Nephron-Specific Knockout of the Epithelial Sodium Channel α-Subunit.” Journal of the American Society of Nephrology : JASN (2015). PMID: 26701978 ↗

    L5OTHERCited in: Staging and Risk Stratification (KDIGO)
  200. [200]

    Pannu N, McBrien KA, Tan Z et al.. “Advancing Community Care and Access to Follow-Up after Acute Kidney Injury Hospitalization: A Randomized Clinical Trial.” Journal of the American Society of Nephrology : JASN (2024). PMID: 39446571 ↗

    L1OTHERCited in: Staging and Risk Stratification (KDIGO)
  201. [201]

    Agarwal R, Green JB, Heerspink HJL et al.. “Impact of Baseline GLP-1 Receptor Agonist Use on Albuminuria Reduction and Safety With Simultaneous Initiation of Finerenone and Empagliflozin in Type 2 Diabetes and Chronic Kidney Disease (CONFIDENCE Trial).” Diabetes care (2025). PMID: 40968755 ↗

    L1RCTCited in: Staging and Risk Stratification (KDIGO), Prognosis and Natural History
  202. [202]

    Ostrominski JW, Mc Causland FR, Claggett BL et al.. “Finerenone Across the Spectrum of Kidney Risk in Heart Failure: The FINEARTS-HF Trial.” JACC. Heart failure (2025). PMID: 40208137 ↗

    L1RCTCited in: Staging and Risk Stratification (KDIGO)
  203. [203]

    Sun J, Liu Q, Seery S et al.. “The impact of hyperkalemia on ICU admission and mortality: a retrospective study of Chinese emergency department data.” BMC emergency medicine (2024). PMID: 38824546 ↗

    L2COHORTCited in: Staging and Risk Stratification (KDIGO)
  204. [204]

    Zheng Q, Wang Y, Yang H et al.. “Cardiac and Kidney Adverse Effects of HIF Prolyl-Hydroxylase Inhibitors for Anemia in Patients With CKD Not Receiving Dialysis: A Systematic Review and Meta-analysis.” American journal of kidney diseases : the official journal of the National Kidney Foundation (2022). PMID: 36396085 ↗

    L1SR_OBSCited in: Acute Management, Long-term and Definitive Management, Renal Replacement Therapy, Transplantation and Electrolyte/Acid-Base Management, Complications
  205. [205]

    Sawinski D, Lindner H, Fitzsimmons R et al.. “Dialysis Nonadherence and Kidney Transplant Outcomes: A Retrospective Cohort Study.” American journal of kidney diseases : the official journal of the National Kidney Foundation (2021). PMID: 34673160 ↗

    L2COHORTCited in: Acute Management, Renal Replacement Therapy, Transplantation and Electrolyte/Acid-Base Management, Prognosis and Natural History
  206. [206]

    Pichitporn W, Kanjanabuch T, Phannajit J et al.. “Efficacy of Potassium Supplementation in Hypokalemic Patients Receiving Peritoneal Dialysis: A Randomized Controlled Trial.” American journal of kidney diseases : the official journal of the National Kidney Foundation (2022). PMID: 35597332 ↗

    L1RCTCited in: Acute Management, Long-term and Definitive Management
  207. [207]

    Chen KT, Kang YN, Lin YC et al.. “Efficacy and Safety of Mineralocorticoid Receptor Antagonists in Kidney Failure Patients Treated with Dialysis: A Systematic Review and Meta-Analysis.” Clinical journal of the American Society of Nephrology : CJASN (2021). PMID: 34117083 ↗

    L1SR_OBSCited in: Acute Management, Complications, Prognosis and Natural History
  208. [208]

    Ito Y, Mizuno M, Suzuki Y et al.. “Long-term effects of spironolactone in peritoneal dialysis patients.” Journal of the American Society of Nephrology : JASN (2013). PMID: 24335969 ↗

    L1RCTCited in: Acute Management, Long-term and Definitive Management, Renal Replacement Therapy, Transplantation and Electrolyte/Acid-Base Management, Complications, Prognosis and Natural History, Special Populations and Prevention
  209. [209]

    Chen N, Hao C, Liu BC et al.. “Roxadustat Treatment for Anemia in Patients Undergoing Long-Term Dialysis.” The New England journal of medicine (2019). PMID: 31340116 ↗

    L1RCTCited in: Acute Management, Long-term and Definitive Management, Renal Replacement Therapy, Transplantation and Electrolyte/Acid-Base Management
  210. [210]

    Vollmer Barbosa C, Lang H, Melk A et al.. “Renal events in patients receiving neprilysin inhibitors: a systematic review and meta-analysis.” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2022). PMID: 35022763 ↗

    L1SR_OBSCited in: Acute Management, Long-term and Definitive Management, Renal Replacement Therapy, Transplantation and Electrolyte/Acid-Base Management
  211. [211]

    Albakr RB, Sridhar VS, Cherney DZI. “Novel Therapies in Diabetic Kidney Disease and Risk of Hyperkalemia: A Review of the Evidence From Clinical Trials.” American journal of kidney diseases : the official journal of the National Kidney Foundation (2023). PMID: 37517546 ↗

    L5TRIAL_NONRANDOMCited in: Acute Management, Long-term and Definitive Management, Renal Replacement Therapy, Transplantation and Electrolyte/Acid-Base Management, Complications
  212. [212]

    Bushinsky DA, Budden JJ, Kalra PA et al.. “Patiromer Treatment in Patients With CKD, Hyperkalemia, and Hyperphosphatemia: A Post Hoc Analysis of 3 Clinical Trials.” American journal of kidney diseases : the official journal of the National Kidney Foundation (2023). PMID: 36965827 ↗

    L2TRIAL_NONRANDOMCited in: Acute Management
  213. [213]

    Walsh M, Manns B, Garg AX et al.. “The Safety of Eplerenone in Hemodialysis Patients: A Noninferiority Randomized Controlled Trial.” Clinical journal of the American Society of Nephrology : CJASN (2015). PMID: 26138259 ↗

    L1RCTCited in: Acute Management, Complications, Prognosis and Natural History, Special Populations and Prevention
  214. [214]

    Cao D, Arens AM, Chow SL et al.. “Part 10: Adult and Pediatric Special Circumstances of Resuscitation: 2025 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care.” Circulation (2025). PMID: 41122889 ↗

    L1GUIDELINECited in: Acute Management, Special Populations and Prevention
  215. [215]

    Ravi KS, Mc Causland FR. “Where next for potassium binders in hemodialysis?” Kidney international (2025). PMID: 40975524 ↗

    L5OTHERCited in: Acute Management, Long-term and Definitive Management, Renal Replacement Therapy, Transplantation and Electrolyte/Acid-Base Management, Complications, Prognosis and Natural History
  216. [216]

    Palmer BF, Clegg DJ. “Gastrointestinal potassium binding in hemodialysis.” Kidney international (2020). PMID: 33126973 ↗

    L5OTHERCited in: Acute Management, Renal Replacement Therapy, Transplantation and Electrolyte/Acid-Base Management, Prognosis and Natural History
  217. [217]

    Bragg-Gresham JL, Fissell RB, Mason NA et al.. “Diuretic use, residual renal function, and mortality among hemodialysis patients in the Dialysis Outcomes and Practice Pattern Study (DOPPS).” American journal of kidney diseases : the official journal of the National Kidney Foundation (2007). PMID: 17336704 ↗

    L2OTHERCited in: Acute Management
  218. [218]

    Gorayeb-Polacchini FS, Moraes TP, Elias RM et al.. “Position Statement of the Brazilian Society of Nephrology on incremental dialysis.” Jornal brasileiro de nefrologia (2026). PMID: 42361228 ↗

    L1GUIDELINECited in: Acute Management, Renal Replacement Therapy, Transplantation and Electrolyte/Acid-Base Management
  219. [219]

    Ellison DH, Terker AS, Gamba G. “Potassium and Its Discontents: New Insight, New Treatments.” Journal of the American Society of Nephrology : JASN (2015). PMID: 26510885 ↗

    L5REVIEW_NARRATIVECited in: Acute Management, Long-term and Definitive Management, Renal Replacement Therapy, Transplantation and Electrolyte/Acid-Base Management
  220. [220]

    Boscardin E, Perrier R, Sergi C et al.. “Plasma Potassium Determines NCC Abundance in Adult Kidney-Specific γENaC Knockout.” Journal of the American Society of Nephrology : JASN (2018). PMID: 29371419 ↗

    L5OTHERCited in: Acute Management, Long-term and Definitive Management, Renal Replacement Therapy, Transplantation and Electrolyte/Acid-Base Management
  221. [221]

    Sterns RH, Rojas M, Bernstein P et al.. “Ion-exchange resins for the treatment of hyperkalemia: are they safe and effective?” Journal of the American Society of Nephrology : JASN (2010). PMID: 20167700 ↗

    L5OTHERCited in: Acute Management, Long-term and Definitive Management
  222. [222]

    Siebert JN, Cheng A, De Masi A et al.. “Augmented Reality-Guided Decision Support in Simulated Pediatric Cardiac Arrest: A Randomized Clinical Trial.” JAMA network open (2026). PMID: 42172032 ↗

    L1RCTCited in: Acute Management, Long-term and Definitive Management, Complications, Special Populations and Prevention
  223. [223]

    Russ P, Morgenschweis M, Einloft J et al.. “Novel Immersive Emergency Training Module to Enhance Clinical Competency in Nephrology.” Clinical journal of the American Society of Nephrology : CJASN (2025). PMID: 40658484 ↗

    L5OTHERCited in: Acute Management
  224. [224]

    Ronksley PE, Tonelli M, Manns BJ et al.. “Emergency Department Use among Patients with CKD: A Population-Based Analysis.” Clinical journal of the American Society of Nephrology : CJASN (2017). PMID: 28119410 ↗

    L2OTHERCited in: Acute Management, Special Populations and Prevention
  225. [225]

    Saglimbene VM, Wong G, Ruospo M et al.. “Fruit and Vegetable Intake and Mortality in Adults undergoing Maintenance Hemodialysis.” Clinical journal of the American Society of Nephrology : CJASN (2019). PMID: 31738182 ↗

    L2OTHERCited in: Acute Management, Complications, Prognosis and Natural History
  226. [226]

    Vaara ST, Reinikainen M, Wald R et al.. “Timing of RRT based on the presence of conventional indications.” Clinical journal of the American Society of Nephrology : CJASN (2014). PMID: 25107952 ↗

    L2OTHERCited in: Acute Management
  227. [227]

    St-Jules DE, Clegg DJ, Palmer BF et al.. “Can Novel Potassium Binders Liberate People with Chronic Kidney Disease from the Low-Potassium Diet? A Cautionary Tale.” Clinical journal of the American Society of Nephrology : CJASN (2021). PMID: 34670798 ↗

    L5REVIEW_NARRATIVECited in: Acute Management, Renal Replacement Therapy, Transplantation and Electrolyte/Acid-Base Management
  228. [228]

    Watson M, Abbott KC, Yuan CM. “Damned if you do, damned if you don't: potassium binding resins in hyperkalemia.” Clinical journal of the American Society of Nephrology : CJASN (2010). PMID: 20798253 ↗

    L5OTHERCited in: Acute Management
  229. [229]

    Bridgeman MB, Shah M, Foote E. “Potassium-lowering agents for the treatment of nonemergent hyperkalemia: pharmacology, dosing and comparative efficacy.” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2019). PMID: 31800078 ↗

    L5REVIEW_NARRATIVECited in: Acute Management, Long-term and Definitive Management, Renal Replacement Therapy, Transplantation and Electrolyte/Acid-Base Management
  230. [230]

    Gregg LP, Navaneethan SD. “Steroidal or non-steroidal MRAs: should we still enable RAASi use through K binders?” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2023). PMID: 36264349 ↗

    L5OTHERCited in: Acute Management, Long-term and Definitive Management, Prognosis and Natural History
  231. [231]

    Arif Y, Wenziger C, Hsiung JT et al.. “Association of serum potassium with decline in residual kidney function in incident hemodialysis patients.” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2022). PMID: 35561740 ↗

    L3OTHERCited in: Acute Management
  232. [232]

    Janjua HS, Mahan JD, Patel HP et al.. “Continuous infusion of a standard combination solution in the management of hyperkalemia.” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2011). PMID: 21220753 ↗

    L4OTHERCited in: Acute Management
  233. [233]

    Ramos CI, González-Ortiz A, Espinosa-Cuevas A et al.. “Does dietary potassium intake associate with hyperkalemia in patients with chronic kidney disease?” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2021). PMID: 33247727 ↗

    L3OTHERCited in: Acute Management, Special Populations and Prevention
  234. [234]

    Deak AT, Belić K, Meissl AM et al.. “Salivary potassium measured by genetically encoded potassium ion indicators as a surrogate for plasma potassium levels in hemodialysis patients-a proof-of-concept study.” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2023). PMID: 35700151 ↗

    L4OTHERCited in: Acute Management
  235. [235]

    Silva CLD, Fonseca PEO, Calice-Silva V et al.. “Efficacy and safety of sacubitril/valsartan in patients on peritoneal dialysis: a systematic review and meta-analysis.” Jornal brasileiro de nefrologia (2026). PMID: 41931676 ↗

    L1SR_OBSCited in: Acute Management, Long-term and Definitive Management, Renal Replacement Therapy, Transplantation and Electrolyte/Acid-Base Management
  236. [236]

    Moncho-Francés F, Gonzales-Candia B, Perez-Silvestre J et al.. “Real-world use of patiromer in patients with hyperkalaemia: A retrospective study from the Valencian Community.” Nefrologia (2026). PMID: 41791977 ↗

    L3COHORTCited in: Acute Management, Renal Replacement Therapy, Transplantation and Electrolyte/Acid-Base Management
  237. [237]

    Chandra A, Rao N, Kulshreshtha MR. “Controlled potassium reduction using dialysate profiling in hyperkalemic hemodialysis patients: A randomized study.” The International journal of artificial organs (2025). PMID: 41185428 ↗

    L1RCTCited in: Acute Management
  238. [238]

    Nasiri H, Mirmazhari A, Mirzakhani L et al.. “Network meta-analysis of HIF-prolyl hydroxylase inhibitors for anemia in dialysis-dependent and non-dialysis CKD: effects on hemoglobin, iron markers, and adverse clinical outcomes.” BMC nephrology (2025). PMID: 41239296 ↗

    L1SR_OBSCited in: Acute Management
  239. [239]

    Kaisar MO, Wiggins KJ, Sturtevant JM et al.. “A randomized controlled trial of fludrocortisone for the treatment of hyperkalemia in hemodialysis patients.” American journal of kidney diseases : the official journal of the National Kidney Foundation (2006). PMID: 16632019 ↗

    L1RCTCited in: Long-term and Definitive Management
  240. [240]

    Desai AS, Webb DJ, Taubel J et al.. “Zilebesiran, an RNA Interference Therapeutic Agent for Hypertension.” The New England journal of medicine (2023). PMID: 37467498 ↗

    L1RCTCited in: Long-term and Definitive Management, Complications
  241. [241]

    Jøns C, Zheng C, Winsløw UCG et al.. “Increasing the Potassium Level in Patients at High Risk for Ventricular Arrhythmias.” The New England journal of medicine (2025). PMID: 40879429 ↗

    L1TRIAL_NONRANDOMCited in: Long-term and Definitive Management, Renal Replacement Therapy, Transplantation and Electrolyte/Acid-Base Management
  242. [242]

    Green JB, Mottl AK, Bakris G et al.. “Design of the COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint study (CONFIDENCE).” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2023). PMID: 35700142 ↗

    L2TRIAL_NONRANDOMCited in: Long-term and Definitive Management, Complications
  243. [243]

    Chen JJ, Lee TH, Yang HY. “Exploring nontraditional cardiorenal advantages of SGLT-2 inhibitors and GLP-1 receptor agonists.” Kidney international (2024). PMID: 38388145 ↗

    L5OTHERCited in: Long-term and Definitive Management
  244. [244]

    Muhammad Daniyal S, Ajaz H, Riaz M et al.. “Combination therapy with mineralocorticoid receptor antagonists and SGLT2 inhibitors versus SGLT2 inhibitor monotherapy in chronic kidney disease: an updated meta-analysis of randomized controlled trials.” BMC nephrology (2025). PMID: 41430169 ↗

    L1SR_MA_RCTCited in: Long-term and Definitive Management
  245. [245]

    Baker M, Perazella MA. “NSAIDs in CKD: Are They Safe?” American journal of kidney diseases : the official journal of the National Kidney Foundation (2020). PMID: 32479922 ↗

    L5REVIEW_NARRATIVECited in: Long-term and Definitive Management, Complications
  246. [246]

    Epstein M, Kovesdy CP, Clase CM et al.. “Aldosterone, Mineralocorticoid Receptor Activation, and CKD: A Review of Evolving Treatment Paradigms.” American journal of kidney diseases : the official journal of the National Kidney Foundation (2022). PMID: 36057467 ↗

    L5REVIEW_NARRATIVECited in: Long-term and Definitive Management, Renal Replacement Therapy, Transplantation and Electrolyte/Acid-Base Management, Complications
  247. [247]

    Gritter M, Wouda RD, Yeung SMH et al.. “Effects of Short-Term Potassium Chloride Supplementation in Patients with CKD.” Journal of the American Society of Nephrology : JASN (2022). PMID: 35609996 ↗

    L2OTHERCited in: Long-term and Definitive Management, Renal Replacement Therapy, Transplantation and Electrolyte/Acid-Base Management, Complications, Special Populations and Prevention
  248. [248]

    Lazelle RA, McCully BH, Terker AS et al.. “Renal Deletion of 12 kDa FK506-Binding Protein Attenuates Tacrolimus-Induced Hypertension.” Journal of the American Society of Nephrology : JASN (2015). PMID: 26432904 ↗

    L4OTHERCited in: Long-term and Definitive Management
  249. [249]

    Dos Santos ECB, de Souza Lima Bitar Y, Dos Anjos JLM et al.. “The impact of a potassium-enriched salt substitute on blood pressure control in patients with resistant arterial hypertension: A randomized pilot trial.” Contemporary clinical trials (2026). PMID: 41571229 ↗

    L1RCTCited in: Long-term and Definitive Management, Special Populations and Prevention
  250. [250]

    Ji S, Vicas M, Franz A et al.. “Arterio-venous metabolite and electrolyte responses to low-load training with and without blood flow restriction versus high-load training to failure.” European journal of applied physiology (2025). PMID: 41359275 ↗

    L1RCTCited in: Long-term and Definitive Management
  251. [251]

    Abouelmagd AA, Ramadan S, Sayed MS et al.. “Efficacy and safety of lorundrostat in uncontrolled hypertension: a meta-analysis.” Naunyn-Schmiedeberg's archives of pharmacology (2025). PMID: 41251750 ↗

    L1SR_OBSCited in: Long-term and Definitive Management
  252. [252]

    Jaisser F, Barrera-Chimal J. “Mineralocorticoid receptor antagonism for non-diabetic kidney disease.” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2025). PMID: 39907538 ↗

    L5REVIEW_NARRATIVECited in: Long-term and Definitive Management
  253. [253]

    Sica DA. “Diuretic use in renal disease.” Nature reviews. Nephrology (2011). PMID: 22183505 ↗

    L5REVIEW_NARRATIVECited in: Long-term and Definitive Management
  254. [254]

    Kamrul-Hasan ABM, Chatterjee S, Nagendra L et al.. “Safety and efficacy of lorundrostat, an aldosterone synthase inhibitor, in patients with uncontrolled hypertension: A systematic review and meta-analysis.” Medicine (2026). PMID: 42260805 ↗

    L1SR_OBSCited in: Long-term and Definitive Management
  255. [255]

    Chen N, Hao C, Peng X et al.. “Roxadustat for Anemia in Patients with Kidney Disease Not Receiving Dialysis.” The New England journal of medicine (2019). PMID: 31340089 ↗

    L1RCTCited in: Renal Replacement Therapy, Transplantation and Electrolyte/Acid-Base Management
  256. [256]

    Weise WJ, Serrano FA, Fought J et al.. “Acute electrolyte and acid-base disorders in patients with ileostomies: a case series.” American journal of kidney diseases : the official journal of the National Kidney Foundation (2008). PMID: 18562060 ↗

    L4CASE_REPORTCited in: Renal Replacement Therapy, Transplantation and Electrolyte/Acid-Base Management, Special Populations and Prevention
  257. [257]

    Hamid AK, Pastor Arroyo EM, Calvet C et al.. “Phosphate Restriction Prevents Metabolic Acidosis and Curbs Rise in FGF23 and Mortality in Murine Folic Acid-Induced AKI.” Journal of the American Society of Nephrology : JASN (2024). PMID: 38189228 ↗

    L4OTHERCited in: Renal Replacement Therapy, Transplantation and Electrolyte/Acid-Base Management, Prognosis and Natural History, Special Populations and Prevention
  258. [258]

    Simmer PE, Perza M, Cho YD et al.. “Hyperkalemic emergency department patients intubated with rocuronium or succinylcholine: Retrospective study of clinical outcomes.” The American journal of emergency medicine (2025). PMID: 41380422 ↗

    L3COHORTCited in: Renal Replacement Therapy, Transplantation and Electrolyte/Acid-Base Management
  259. [259]

    Sohara E, Uchida S. “Kelch-like 3/Cullin 3 ubiquitin ligase complex and WNK signaling in salt-sensitive hypertension and electrolyte disorder.” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2015). PMID: 26152401 ↗

    L5REVIEW_NARRATIVECited in: Renal Replacement Therapy, Transplantation and Electrolyte/Acid-Base Management
  260. [260]

    Silva AKFD, Oliveira AG, Marques DP et al.. “Catecholamines and serum potassium alterations in critically ill neonates: a prospective cohort study.” Critical care science (2026). PMID: 41849521 ↗

    L2COHORTCited in: Renal Replacement Therapy, Transplantation and Electrolyte/Acid-Base Management
  261. [261]

    Tu KC, Weng YC, Liao CT et al.. “The effectiveness and safety of sacubitril/valsartan in real-world dialysis patients with heart failure reduced ejection fraction.” Medicine (2026). PMID: 41630233 ↗

    L2SR_OBSCited in: Renal Replacement Therapy, Transplantation and Electrolyte/Acid-Base Management
  262. [262]

    Rossignol P, Frimat L, Zannad F. “The safety of mineralocorticoid antagonists in maintenance hemodialysis patients: two steps forward.” Kidney international (2019). PMID: 30904064 ↗

    L5OTHERCited in: Prognosis and Natural History
  263. [263]

    Dibo P, Mareddy NSR, Kojima GSA et al.. “Efficacy and safety of mineralocorticoid receptor antagonists in kidney transplant patients: an updated meta-analysis of randomized controlled trials.” BMC nephrology (2025). PMID: 40770304 ↗

    L1SR_MA_RCTCited in: Prognosis and Natural History
  264. [264]

    Wen CF, Chuang MH, Wu VC et al.. “Efficacy of combined sodium-glucose cotransporter 2 inhibitors and finerenone in chronic kidney disease: a systematic review and meta-analysis.” Frontiers in pharmacology (2026). PMID: 42212277 ↗

    L1SR_OBSCited in: Prognosis and Natural History
  265. [265]

    Pozueco Zaffari G, Noguero Duarte L, Queiroz I et al.. “Effectiveness of Sodium Bicarbonate Administration in Out-of-Hospital Cardiac Arrests: An Updated Systematic Review and Meta-Analysis.” Prehospital emergency care (2025). PMID: 41091632 ↗

    L1SR_OBSCited in: Prognosis and Natural History
  266. [266]

    Meng Y, Zhang JW, Zhang YJ et al.. “Associations between Carvedilol Use and Outcomes in Critically Ill Patients with Acute Kidney Injury: A Multicenter Retrospective Cohort Study.” American journal of nephrology (2025). PMID: 41452793 ↗

    L3COHORTCited in: Prognosis and Natural History
  267. [267]

    Byrne C, Krogager ML, Kragholm K et al.. “The association between arrival potassium and 30-day survival following resuscitation from out-of-hospital cardiac arrest: a retrospective cohort study.” Scandinavian journal of trauma, resuscitation and emergency medicine (2025). PMID: 40859315 ↗

    L2COHORTCited in: Prognosis and Natural History
  268. [268]

    Tuot DS, Plantinga LC, Hsu CY et al.. “Chronic kidney disease awareness among individuals with clinical markers of kidney dysfunction.” Clinical journal of the American Society of Nephrology : CJASN (2011). PMID: 21784832 ↗

    L2OTHERCited in: Prognosis and Natural History
  269. [269]

    Kohan DE, Fioretto P, Tang W et al.. “Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control.” Kidney international (2013). PMID: 24067431 ↗

    L1RCTCited in: Special Populations and Prevention
  270. [270]

    Frimodt-Møller M, Høj Nielsen A, Strandgaard S et al.. “Feasibility of combined treatment with enalapril and candesartan in advanced chronic kidney disease.” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2009). PMID: 19903661 ↗

    L1RCTCited in: Special Populations and Prevention
  271. [271]

    Luciano RL. “Acute kidney injury from cherry concentrate in a patient with CKD.” American journal of kidney diseases : the official journal of the National Kidney Foundation (2013). PMID: 24290246 ↗

    L4CASE_REPORTCited in: Special Populations and Prevention

Revision History

All updates applied to this page

Loading revisions…